<SEC-DOCUMENT>0001193125-16-656706.txt : 20160725
<SEC-HEADER>0001193125-16-656706.hdr.sgml : 20160725
<ACCEPTANCE-DATETIME>20160725172219
ACCESSION NUMBER:		0001193125-16-656706
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20160725
DATE AS OF CHANGE:		20160725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-212674
		FILM NUMBER:		161782706

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d219508ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July&nbsp;25, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-3
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALENA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>20-8099512</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2000 Crow Canyon Place, Suite 380 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Ramon, California 94583 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(855) 855-4253 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mark W.
Schwartz, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galena Biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2000 Crow Canyon Place, Suite 380 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Ramon, California 94583 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(855) 855-4253 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Thomas J. Knapp</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Christopher J. Melsha</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>General Counsel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Fredrikson &amp; Byron P.A.</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Galena Biopharma, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>200 South Sixth Street</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2000 Crow Canyon Place, Suite 380</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Suite 4000</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>San Ramon, California 94583</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Minneapolis, Minnesota 55402</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>(855) 855-4253</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(612) 492-7369</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest
reinvestment plans, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to
Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. (Check one): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;(Do not check if a small reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>offering
price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per share(2)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>offering price(2)</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registration fee</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">3,658,012 shares</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$0.4075</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1,490,640.20</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$150.11</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Rule 416 under the Securities Act of 1933, there is also being registered hereunder such indeterminate number of additional shares of common stock as may be issuable with respect to the shares being
registered hereunder as a result of stock splits, stock dividends or similar transactions. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933 based upon the average of the high and low prices of the registrant&#146;s common stock on
July 18, 2016. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration
statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED JULY&nbsp;25, 2016 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g219508covpg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>3,658,012 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by the selling stockholders identified in this prospectus of up to 3,658,012 shares of our common stock.&nbsp;We
are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
selling stockholders may sell the shares of common stock described in this prospectus in a number of different ways and at varying prices. See &#147;Plan of Distribution&#148; for more information about how the selling stockholders may sell the
shares of common stock being offered pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay the expenses incurred in registering the shares, including legal and
accounting fees. See &#147;Plan of Distribution&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The NASDAQ Capital Market under the symbol &#147;GALE.&#148; On
July&nbsp;22, 2016, the closing sale price of our common stock on The NASDAQ Capital Market was $0.45. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>An investment in our common
stock involves a high degree of risk. See &#147;<A HREF="#toc219508_4">Risk Factors</A>&#148; beginning on page&nbsp;11 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE <A NAME="toc"></A>OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_3">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_9">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc219508_14">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THI<A NAME="toc219508_1"></A>S PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC. As permitted by
the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If information in this prospectus is inconsistent with any document incorporated by reference that was filed with the SEC before the date of
this prospectus, you should rely on this prospectus. This prospectus and the documents incorporated by reference into this prospectus include important information about us, the securities being offered and other information you should know before
investing in our securities. You should also read and consider information in the documents to which we have referred you in the section of this prospectus entitled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should rely only on this prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus. We have
not authorized anyone to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on
it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that
the information contained or incorporated by reference in this prospectus is accurate as of any date other than as of the date of this prospectus, or in the case of the documents incorporated by reference, the date of such documents regardless of
the time of delivery of this prospectus or any sale of our shares of common stock. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be
a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately
representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained or incorporated by reference in this
prospectus concerning our industry, including our general expectations and market opportunity, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and
studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition,
assumptions and estimates of our and our industry&#146;s future performance are necessarily uncertain due to a variety of factors, including those described in &#147;Risk Factors&#148; beginning on page&nbsp;11 of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPE<A NAME="toc219508_2"></A>CTUS SUMMARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere in this prospectus or incorporated by reference into this prospectus and
does not contain all of the information that may be important to you or that you should consider before investing in our common stock. This prospectus includes or incorporates by reference information about the securities we are offering, as well as
information regarding our business and detailed financial data. Before making an investment decision, you should read this prospectus and the information incorporated by reference herein in their entirety, including &#147;Risk Factors&#148;
beginning on page 11 of this prospectus. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>About Galena </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc.
(&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Galena&#148; or the &#147;company&#148;) is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical
needs. Galena&#146;s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company&#146;s pipeline consists
of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax&#153; (nelipepimut-S), GALE-301 and GALE-302. The company is also developing a hematology asset, GALE-401, a controlled release version of
the approved drug anagrelide for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count. NeuVax is currently in several concurrent Phase 2 trials ongoing both as a single
agent and in combination with other therapies. GALE-301 is in a Phase&nbsp;2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302. <FONT STYLE="white-space:nowrap">GALE-401</FONT> has
completed a Phase 2 trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are seeking to build value for shareholders through pursuit of the following objectives: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Develop novel cancer immunotherapies to address unmet medical needs through the use of peptide-based vaccines targeting well-established tumor antigens. One of our key strategies is to target the adjuvant setting in
patients with higher risk of recurrence, who had their primary treatment for cancer and have no evidence of disease, and are more likely to benefit from treatment via immunotherapy. Our immunotherapy programs are currently targeting two key areas:
secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Diversifying our pipeline with clinical development programs in other areas of oncology. Our hematology asset is targeting the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to
reduce the elevated platelet count. Myeloproliferative neoplasms (MPNs) are a closely related group of hematological malignancies in which the bone marrow cells that produce the body&#146;s blood cells develop and function abnormally.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition
of additional oncology programs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the current status of our clinical development pipeline: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g219508txpg03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Novel Cancer Immunotherapies </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our targeted cancer immunotherapy approach is currently based upon two key areas: preventing secondary recurrence of cancer, which is becoming
increasingly important as the number of cancer survivors continues to grow; and, primary prevention intended to treat breast cancer earlier in the treatment spectrum. Once a patient&#146;s tumor becomes metastatic, the outcome is often fatal, making
the prevention of recurrence a potentially critical component of overall patient care. Our programs primarily target patients in the adjuvant (after-surgery) setting who have relatively healthy immune systems, but may still have residual disease.
Minimal residual disease, or single cancer cells (occult cancer cells) or micrometastasis, that are undetectable by current radiographic scanning technologies, can result in disease recurrence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating
factor (rhGM-CSF), and work by harnessing the patient&#146;s own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many potential clinical advantages, including a favorable safety profile, since these drugs
may lack the toxicities typical of most cancer therapies. They also have the potential to evoke long-lasting protection through activation of the immune system and a convenient, intradermal mode of delivery. We are currently engaged in multiple
clinical trials with NeuVax&#153; (nelipepimut-S), GALE-301, and GALE-302, targeting the prevention of recurrence in breast, gastric, ovarian and endometrial cancers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeuVax&#153; (nelipepimut-S) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NeuVax&#153; (nelipepimut-S) is a cancer immunotherapy targeting human epidermal growth factor receptor (HER2) expressing cancers. NeuVax is
the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established and validated target for therapeutic intervention in breast and gastric carcinomas. The NeuVax vaccine is combined with GM-CSF for injection
under the skin, or intradermal administration. Data has shown that an increased presence of circulating tumor cells (CTCs) may predict Disease Free Survival (DFS) and Overall Survival (OS) suggesting a presence of isolated micrometastases, not
detectable clinically, but, over time, can lead to recurrence, most often in distant sites. After binding to the specific HLA molecules on antigen presenting cells, the nelipepimut-S sequence stimulates specific cytotoxic T lymphocyte, or CTLs,
causing significant clonal expansion. These activated CTLs recognize, neutralize and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate
CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Breast Cancer</U>: According to the National Cancer Institute (NCI), over 230,000 women in the
U.S. are diagnosed with breast cancer annually. While improved diagnostics and targeted therapies have decreased breast cancer mortality in the U.S., metastatic breast cancer remains incurable. Approximately 75% to 80% of breast cancer patients have
tissue test positive for some increased amount of the HER2 receptor, which is associated with disease progression and decreased survival. Only approximately 20% to 30% of all breast cancer patients&#151;those with HER2 immunohistochemistry (IHC) 3+
disease, or IHC 2+ and fluorescence in situ hybridization (FISH) amplified&#151;have a HER2 directed, approved treatment option available after their initial standard of care. This leaves the majority of breast cancer patients with
low-to-intermediate HER2 expression (IHC 1+/2+) ineligible for therapy and without an effective targeted treatment option to prevent cancer recurrence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have multiple trials currently ongoing with NeuVax. On June&nbsp;24, 2016, the assembled Independent Data Monitoring Committee, or IDMC,
met to conduct a pre-planned safety and futility analysis of the Phase 3 PRESENT (<B>P</B>revention of&nbsp;<B>R</B>ecurrence in&nbsp;<B>E</B>arly-<B>S</B>tage, Node- Positive Breast Cancer with Low to Intermediate HER2&nbsp;<B>E</B>xpression
with&nbsp;<B>NeuVax T</B>reatment) clinical trial. On June&nbsp;27, 2016, the IDMC recommended that the Phase 3 trial &#147;be stopped for futility unless it is determined that there has been a systematic reversal in the study drug treatments in the
two arms, in which case the IDMC should reevaluate the clinical evidence.&#148; We have stopped the PRESENT trial, and initiated an investigation into the causes of the recommendation. We currently have two additional Phase 2 breast cancer trials
ongoing with NeuVax in combination with trastuzumab (Herceptin&reg;; Genentech/Roche) targeting the prevention of recurrence in expanded indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also recently announced our intent to initiate a Phase 2 trial with NeuVax as a single agent in patients with ductal carcinoma in situ, or
DCIS, in collaboration with the NCI, potentially positioning NeuVax as a treatment for earlier stage disease. The trial will have an immunological endpoint evaluating NeuVax peptide-specific cytotoxic T lymphocyte (CTL; CD8+ T-cell) response in
vaccinated patients. DCIS is defined by the NCI as a noninvasive condition in which abnormal cells are found in the lining of a breast duct, and is the most common type of breast cancer. The abnormal cells have not spread outside the duct to other
tissues in the breast. In some cases, DCIS may become invasive cancer and spread to other tissues, and at this time, there is no way to know which lesions could become invasive. Current treatment options for DCIS include breast-conserving surgery
and radiation therapy with or without tamoxifen, breast-conserving surgery without radiation therapy, or total mastectomy with or without tamoxifen. According to the American Cancer Society, in 2015 there were over 60,000 diagnoses of DCIS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Gastric Cancer</U>: According to the NCI, gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the
stomach. Almost all gastric cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas.
Infection with bacteria called Helicobacter pylori (H. pylori) is a common cause of gastric cancer and age, diet, and stomach disease can affect the risk of developing gastric cancer. Gastric cancer is often diagnosed at an advanced stage because
there are no early signs or symptoms. Gastric, or stomach cancer, is the second-most common cancer among males and third-most common among females in Asia and worldwide with over 63,000 new cases a year in India, where an initial clinical trial of
NeuVax will be run. Overexpression of the HER2 receptor occurs in approximately 20% of gastric and gastro-esophageal junction adenocarcinomas, predominantly those of the intestinal type. Overall, without regard to the stage of cancer, only
approximately 28% of patients with stomach cancer live at least five years following diagnosis and new adjuvant treatments are needed to prevent disease recurrence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently have a number of ongoing or planned clinical trials designed to expand the clinical and geographical footprint of NeuVax: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2b Ongoing: A randomized, multicenter, investigator-sponsored, 300 patient Phase 2b clinical trial is enrolling HER2 1+/2+ node-positive and high-risk node-negative breast cancer patients who are HLA A2, A3, A24
and/or A26 positive to study NeuVax in combination with trastuzumab in the adjuvant setting. This investigator sponsored trial (IST) is co-funded by Genentech/Roche (providing both trastuzumab and monetary support) and Galena (providing NeuVax and
monetary support). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 Ongoing: An IST is also ongoing to study NeuVax in combination with trastuzumab in node positive and negative HER2 IHC 3+ patients or HER2 gene-amplified breast cancer patients who are HLA A2 and/or HLA A3
positive and are determined to be at high-risk for recurrence. The study plans to enroll 100 women. Partial funding for this trial comes from the Department of Defense through the Congressionally Directed Medical Research Program via legislation
known as the Defense Appropriations Act. The grant was awarded under a Breast Cancer Research Program with the Breakthrough Award given to the lead investigator for the trial. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 Planned: A clinical trial, entitled, VADIS (Phase 2 trial of the nelipepimut-S Peptide&nbsp;<B>VA</B>ccine in Women with&nbsp;<B>D</B>C<B>IS</B>&nbsp;of the Breast) is open for patient recruitment. The Phase 2
trial will be a single-blind, double arm, randomized, controlled trial in pre- or post-menopausal patients with DCIS who are HLA-A2 positive with HER2 expression of IHC 1+, 2+, or 3+. VADIS will be co-funded by and run in collaboration with the
National Cancer Institute, or NCI. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 Planned: A Phase 2 clinical trial in patients with gastric cancer is expected to initiate in 2016. The trial will be run in India by our partner, Dr.&nbsp;Reddy&#146;s Laboratories, Ltd., as part of our NeuVax
commercialization agreement in that region with Dr.&nbsp;Reddy&#146;s. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GALE-301 and GALE-302 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our second immunotherapy franchise targets folate binding protein (FBP) receptor-alpha. FBP is a well-validated therapeutic target that is
highly over-expressed in ovarian, endometrial and breast cancers, and is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes to recognize and destroy FBP-expressing cancer cells. Current treatments after surgery for these
diseases are principally with platinum based chemotherapeutic agents. These patients suffer a high recurrence rate and most relapse with an extremely poor prognosis. GALE-301 and GALE-302 are immunogenic peptides that consist of a peptide derived
from FBP combined with GM-CSF for the prevention of cancer recurrence in the adjuvant setting. GALE-301 is the E39 peptide, while GALE-302 is an attenuated version of this peptide, known as E39. Two trials are ongoing with our FBP peptides: the <FONT
STYLE="white-space:nowrap">GALE-301</FONT> Phase 2a portion of the Phase 1/2a clinical trial is ongoing in ovarian and endometrial adenocarcinomas, and the GALE-301 plus GALE-302 Phase 1b clinical trial is ongoing in breast and ovarian cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><U>Ovarian Cancer</U>: According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program, new cases of ovarian cancer occur at
an annual rate of 11.9&nbsp;per 100,000 women in the United States, with an estimated 22,280 cases for 2016. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths
in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 - 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with
ovarian cancer is 45.6%. Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 80% of women presenting with advanced-stage (III or IV) disease. These patients
have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the
majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy is approximately 70%. Unfortunately for these women, once the disease recurs, treatment options are
limited and the disease is most likely incurable. According to the NCI SEER Program, new cases of endometrial cancer occur at an annual rate of 25.1&nbsp;per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial
cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 - 2012
data). The prevalence of endometrial cancer in the U.S. is about 620,000 women. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Hematology </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GALE-401 (anagrelide controlled release (CR)) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">GALE-401 (Anagrelide Controlled Release) contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with
myeloproliferative neoplasms (MPNs) to lower abnormally elevated platelet levels. The currently available immediate release (IR) version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent. These
adverse events may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration (Cmax) is hypothesized to reduce the side effects, but preserve efficacy, potentially allowing a broader use of the drug. Multiple Phase 1
studies in 98 healthy subjects have shown GALE-401 reduces the Cmax of anagrelide following oral administration, appears to be well tolerated at the doses administered, and to be capable of reducing platelet levels. The Phase 1 program provided the
desired PK/PD (pharmacokinetic/pharmacodynamic) profile to enable the initiation of a Phase&nbsp;2 proof-of-concept trial. The Phase 2, open label, single arm, proof-of-concept trial enrolled 18 patients in the United States for the treatment of
thrombocytosis, or elevated platelet counts in patients with MPNs. Final safety and efficacy data from this pilot Phase 2 trial was presented in December 2015 and demonstrated a prolonged clinical benefit with a potentially improved safety profile.
The follow-up portion of the Phase 2 is now complete and we plan to submit a final Phase 2 manuscript at the end of 2016. We continue to review our data and are analyzing the treatment landscape for MPNs, with a current focus on Essential
Thrombocythemia (ET). We are planning to meet with the FDA later this year to discuss our Phase 2 data, our development opportunities in MPN patients, and confirm the 505(b)2 regulatory pathway for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">MPNs are a closely related group of hematological malignancies in which the bone marrow cells that produce the body&#146;s blood cells develop
and function abnormally. The main MPNs are ET, Polycythemia Vera (PV), Primary Myelofibrosis (PMF), and Chronic Myelogenous Leukemia (CML), all of which are associated with high platelet counts. ET is an acquired disease of the bone marrow and is
associated with vascular complications including thrombosis and bleeding events. The MPNs are progressive blood cancers that can strike anyone at any age. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alliance Partners in Therapeutic Areas </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively looking to leverage our technology platforms by seeking to work with pharmaceutical and biotechnology partners in a number of
therapeutic areas in oncology. Our team has experience targeting products in multiple indications, and based on this experience, we believe we can expand the clinical utility of our current development candidates as well as discover more drug
candidates by working with partners than we can develop with our own resources. We are seeking to work with partners in the discovery and development of drugs in a number of therapeutic areas and technology platforms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patents and other
intellectual property rights are crucial to our success. It is our policy to protect our intellectual property rights through available means, including filing and prosecuting patent applications in the U.S. and other countries, protecting trade
secrets, and utilizing regulatory protections such as data exclusivity. We also include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements
with our employees, consultants, clinical investigators and scientific advisors to protect our confidential information and know-how. Together with our licensors, we also rely on trade secrets to protect our combined technology especially where we
do not believe patent protection is appropriate or obtainable. It is our policy to operate without infringing on, or misappropriating, the proprietary rights of others. The following chart summarizes our intellectual property rights. The patents for
the products are for the U.S. and certain foreign countries: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:55.35pt; font-size:8pt; font-family:Times New Roman"><B>Drug Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Scope</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exclusivity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:37.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Period</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153;&nbsp;(nelipepimut-S)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Breast cancer recurrence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2028</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; (nelipepimut-S)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Gastric</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2028</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; (nelipepimut-S)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">DCIS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2028</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; in combination with trastuzumab</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Breast&nbsp;cancer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NeuVax&#153; in combination with other compounds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Breast&nbsp;cancer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2037</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GALE-301 &amp; GALE-302</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Breast, ovarian and endometrial cancer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2035</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GALE-401 (Anagrelide Controlled Release)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Platelet Lowering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Pending and/or issued</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2029</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Out-License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceuticals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective
December&nbsp;3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (&#147;ABIC&#148;). Under the agreement, we granted ABIC exclusive rights to seek marketing approval in Israel
for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC&#146;s rights also
include a right of first refusal in Israel for all future indications for which NeuVax may be approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the license and supply
agreement, ABIC will assume responsibility for regulatory registration of NeuVax in Israel, provide financial support for local development, and commercialize the product in the region in exchange for making royalty payments to us based on future
sales of NeuVax. ABIC also agrees in the license and supply agreement to purchase all supplies of NeuVax from us at a price determined according to a specified formula. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Reddy&#146;s Laboratories Ltd. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;14, 2014, we entered into a strategic development and commercialization partnership with Dr.&nbsp;Reddy&#146;s
Laboratories Ltd. (&#147;Dr. Reddy&#146;s&#148;), under which we licensed commercial rights in India to Dr.&nbsp;Reddy&#146;s for NeuVax in breast and gastric cancers. Under the agreement, Dr.&nbsp;Reddy&#146;s will lead the Phase 2 development of
NeuVax in India in gastric cancer, significantly expanding the potential patient population addressable with NeuVax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kwangdong Pharmaceutical Co., Ltd. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;30, 2009, we entered into a license agreement with Kwangdong Pharmaceutical Co, Ltd (Kwangdong). Under the agreement, we
granted Kwangdong exclusive rights to seek marketing approval in The Republic of Korea (South Korea) for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to
market, sell and distribute NeuVax in South Korea assuming such approval is obtained. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments (in reverse chronological order) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Discontinued NeuVax&#153; (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee
Recommendation </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2016, the assembled IDMC met to conduct a pre-planned safety and futility analysis of the
Phase 3 PRESENT (<B>P</B>revention of <B>R</B>ecurrence in&nbsp;<B>E</B>arly-<B>S</B>tage, Node- Positive Breast Cancer with Low to Intermediate HER2&nbsp;<B>E</B>xpression with&nbsp;<B>NeuVax T</B>reatment) Trial. On June&nbsp;27, 2016, the IDMC
recommended that the study be stopped for futility unless it is determined that there has been a systematic reversal in the study drug treatments in the two arms, in which case the IDMC should reevaluate the clinical evidence. We have stopped the
PRESENT Trial, and initiated an investigation into the causes of the recommendation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Derivative and Securities Litigation &#150;
The U.S. District Court for the District of Oregon granted final approval of the settlements previously reported. </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;3, 2015, we reached an agreement in principle to settle the consolidated shareholder derivative action,&nbsp;<I>In re</I>&nbsp;<I>Galena Biopharma, Inc. Derivative Litigation,</I>&nbsp;Civil Action No.&nbsp;3:14-cv-00382-SI against us
and certain of our current and former officers and directors. Following the hearing on June&nbsp;23, 2016, on June&nbsp;24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in&nbsp;<I>In re Galena
Biopharma, Inc. Derivative Litigation</I>, granting final approval to the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#146;s fees of $4.5 million plus costs, which will be paid by our insurance carriers.
The settlement includes a payment of $15 million in cash by our insurance carriers, which we will use to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also requires
that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former
officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit,<I>&nbsp;</I><I>In re
Galena Biopharma, Inc. Securities Litigation</I>, Civil Action No.&nbsp;3:14-cv-00367-SI, against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon.
Following the hearing on June&nbsp;23, 2016, on June&nbsp;24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in&nbsp;<I>In re Galena Biopharma, Inc. Securities Litigation</I>, granting final
approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#146;s fees of $4.5 million plus costs, which is paid out of the settlement funds. The agreement provides for a settlement payment of $20
million to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid by our
insurance carriers and $2.3 million in cash was paid by us on July&nbsp;1, 2016, along with $1 million in shares of our common stock (480,053 shares) paid by us on July&nbsp;6, 2016. We will be responsible for defense costs and any settlements or
judgments incurred for any related opt-out lawsuits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Securities Litigation Opt Out Claims </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have resolved claims brought by shareholders and others that relate to the securities litigation mentioned above in one case for $150,000
plus $150,000 in shares (291,262)&nbsp;of our common stock, and in another case for $1.5 million in shares of our common stock (3,366,750 shares). The shares issued in connection with such settlements are included in the offering covered by this
prospectus.&nbsp;The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in
connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Presented GALE-401 Combined Safety Data </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;13, 2016 we presented combined safety data from our GALE-401 clinical trials at the European Hematology Association 21<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>Congress. A total of six trials have been run with GALE-401, five Phase 1 trials in healthy volunteers (N=98), and one Phase 2 single arm, open label pilot study in MPN patients (N=18). The poster,
entitled, &#147;<I>Anagrelide Controlled Release (GALE-401) Safety Profile Consistently Well Tolerated in Myeloproliferative Neoplasms Patients and Healthy Volunteers&#148;</I>&nbsp;was designed to characterize the safety profile of GALE-401 in all
subjects treated to date. The results demonstrated that GALE-401 is well tolerated in MPN patients as well as in healthy volunteers and we observed predominantly mild to moderate toxicities that did not reveal any unexpected AEs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Received Two Orphan Drug Designations for GALE-301 and GALE-301/GALE-302 </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2016, we announced that the U.S. Food and Drug Administration, or FDA, granted two orphan-drug designations for Galena&#146;s
two cancer immunotherapy peptides derived from Folate Binding Protein (FBP) for the treatment (including prevention of recurrence) of ovarian cancer: one for GALE-301 (E39), and one for GALE-301 (E39) and GALE-302 (E39&#146;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Presented GALE-301 Phase 1/2a Primary Analysis </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2016, we presented the primary analysis from the Company&#146;s GALE-301 Phase 1/2a clinical trial at the American Society of
Clinical Oncology Annual Meeting 2016. The poster, entitled, &#147;<I>The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent
recurrence,&#148;</I>&nbsp;demonstrated that the vaccine is well tolerated and immunogenic. In the optimal dose group, the results demonstrate potential clinical benefit for GALE-301 to prevent recurrence in these patients, and that boosters may
sustain this effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><U>Received Fast Track Designation for NeuVax&#153; (nelipepimut-S) PRESENT Clinical Trial </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;1, 2016, we announced that the FDA has designated NeuVax&#153; (nelipepimut-S), combined GM-CSF, as a Fast Track development
program for the treatment of patients with early stage, node positive breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, following standard of care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Operating Results and Financial Condition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had cash and cash equivalents of approximately $19.6 million as of June&nbsp;30, 2016. In addition, we had approximately $24 million of
restricted cash that is reserved for a lender who has the option to redeem all, or part, of such amount within 30 days of our public announcement on June&nbsp;29, 2016, of the discontinuation of the Phase 3 PRESENT Trial upon the IDMC&#146;s
recommendation dated June&nbsp;27, 2016. As of the date of this prospectus, the lender has not redeemed the approximately $24 million in full or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had no revenue for the quarter ending June&nbsp;30, 2016, and our cash burn from operations for the quarter ending June&nbsp;30, 2016 was
approximately $13 million. In addition, we paid off our loan with Oxford Finance LLC for a total of $3.1 million. The Company has stopped the PRESENT Trial and is running an investigation that is estimated to cost between $250,000 and $500,000 over
the next three months. Depending on the outcome of the investigation, the estimated cost to close out the PRESENT Trial will be between $4 million to $7 million. On July&nbsp;1, 2016, we paid $2.3 million for the securities class action settlement.
We believe that our existing cash and cash equivalents together with the net proceeds of $11.7 million we received on July 13, 2016 from selling 28,000,000 shares of common stock and 14,000,000 warrants (the &#147;July Financing&#148;) should be
sufficient to fund our operations for at least six months. This projection is based on our current planned operations, stopping the PRESENT Trial and investigation of the causes of the failure of such clinical trial, anticipated payments for defense
costs for the cooperation and discussions with the staff in the SEC investigation and other governmental investigations, and is subject to changes in our plans and uncertainties inherent in our business. We will need to seek to replenish our
existing cash and cash equivalents prior to the end of 2016. We also have funding available under our purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with MLV&nbsp;&amp; Co. and Maxim Group LLC described in the previously
filed prospectuses, but there is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of our future funding needs. Additionally, in connection with the July Financing, we have agreed not to
issue any shares of our common stock (including under our purchase agreement with Lincoln Park Capital Fund, LLC and under our sales agreements with MLV&nbsp;&amp; Co. and Maxim Group LLC) for a period of 75 days from the date of the closing of the
July Financing. At our annual meeting of stockholders adjourned on July 15, 2016, our stockholders approved an increase in our authorized common stock from 275,000,000 to 350,000,000. We are not able to predict whether these additional shares will
be sufficient based upon our current stock price to meet the Company&#146;s ongoing financing requirements to maintain the Company&#146;s operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we fail to obtain additional future funding when needed, we could be forced to scale back or
terminate our operations, or to seek to merge with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to
continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Secured Debentures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May 10,
2016, we entered into a Securities Purchase Agreement, with JGB (Cayman) Newton Ltd., or JGB, pursuant to which we sold, at a 6.375% original issue discount, a total of $25,530,000 Senior Secured Debentures, or the Debentures, and warrants to
purchase up to 2.0 million shares of our common stock. Net proceeds to us from sale of the Debentures, after payment of commissions and legal fees, were approximately $23,400,000. The Debentures mature November 10, 2018, and accrue interest at 9%
per year and contain no conversion features to shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Debentures carry an interest only period of six months
following which the holder shall have the rights, at its option, to require us to redeem up to $1,100,000 of the outstanding principal amount of these Debentures. Interest is payable at the end of each month based on the outstanding principal. We
are required to promptly, but in any event no more than three trading days after the holder delivers a redemption notice to us, to pay the applicable redemption amount in cash or, at our election and subject to certain conditions, in shares of our
common stock. If we elect to pay the redemption amount in shares of our common stock, then the shares will be delivered at the lesser of A) 7.5% discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or
B) a 7.5% discount to the prior trading day&#146;s volume weighted average price. We may only opt for payment in shares of common stock if certain equity conditions are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As noted above, because the interim analysis of the PRESENT Trial resulted in a discontinuation of the study, JGB has the right to require us
to prepay in cash all, or any portion, of the outstanding principal amount of this Debenture funded in cash by JGB on the closing date, plus all accrued and unpaid interest. If JGB elects such prepayment of the Debentures, then the number of shares
subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by us. In addition to the Debenture, JGB received a Series A warrant to purchase 1 million shares
upon the closing on the sale of the Debentures at an exercise price of $1.51.&nbsp;The Series A warrant is exercisable beginning November&nbsp;10, 2016 and for a period of five years thereafter.&nbsp;Additionally, in accordance with the terms of the
Securities Purchase Agreement, we issued to JGB a Series B warrant to purchase 1 million shares upon our announcement on June 29, 2016, of the interim analysis conducted by the Independent Data Monitoring Committee of the PRESENT Trial at an
exercise price of $0.43.&nbsp;The Series B warrant is exercisable beginning November 10, 2016 and for a period of five years thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our obligations under the Debentures can be accelerated in the event we undergo a change in control and other customary events of default. In
the event of default and acceleration of our obligations, we would be required to pay an amount equal to 103.5% of all amounts of principal and interest then outstanding under the Debentures in cash. Our obligations under the Debentures are secured
under a Security Agreement by a senior lien on all of our assets, including all of our interests in our consolidated subsidiaries. We must also have maintained a minimum of $24.0 million in cash through the date of the public announcement of the
interim analysis of the PRESENT Trial. If the trial had not been discontinued as a result of the interim analysis then the minimum cash requirement would have been reduced to $12.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Armentum Partners, LLC, or Armentum, acted as the placement agent in the offering of the Debentures and we agreed to pay Armentum a fee equal
to 2% of the funds received from the sale of the Debentures. We paid half of the placement fee upon funding with the remaining payable unless we prepay the loan, or any portion, of all outstanding principal amounts of the Debentures if the PRESENT
trial is discontinued for certain specified reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 2000 Crow Canyon Place, Suite 380, San Ramon, California 94583, and our phone number is
(855)&nbsp;855-4253. Our website address is www.galenabiopharma.com. We do not incorporate the information on our website into this prospectus, and you should not consider such information part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated as Argonaut Pharmaceuticals, Inc. in Delaware on April&nbsp;3, 2006 and changed our name to RXi Pharmaceuticals
Corporation on November&nbsp;28, 2006. On September&nbsp;26, 2011, we changed our company name from RXi Pharmaceuticals Corporation to Galena Biopharma, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be offered by the selling stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3,658,012 shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shares&nbsp;outstanding&nbsp;after this&nbsp;offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">185,495,130 shares (excluding treasury shares) and without giving effect to any other issuances of common stock subsequent to the date hereof.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We will receive none of the proceeds from the sale of shares by the selling stockholders in this offering. See &#147;Use of Proceeds.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dividend policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We do not anticipate paying any cash dividends on our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trading</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our common stock is traded on The NASDAQ Capital Market under the symbol &#147;GALE.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; beginning on page 11 of this prospectus and the documents incorporated by reference in this prospectus.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock shown above to be outstanding after this offering is based on 181,837,117 shares
outstanding as of March 31, 2016 and excludes as of such date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">675,000 shares held in treasury; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">12,000,552 shares of our common stock subject to outstanding options having a weighted-average exercise price of $2.59 per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">9,398,650 shares of our common stock reserved for issuance in connection with future awards under our 2007 stock incentive plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">461,113 shares of our common stock reserved for sale under our employee stock purchase plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">35,775,656 shares of our common stock subject to outstanding warrants having a weighted-average exercise price of $1.84 per share. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock issuable upon the exercise of our outstanding warrants and the exercise prices thereof are subject to adjustment in
certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTE REGARDING FOR<A NAME="toc219508_3"></A>WARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus and the other documents we have filed with the SEC that are incorporated herein by reference contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of financing needs, revenue, expenses,
earnings or losses from operations, or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning product research, development and commercialization plans and
timelines, any statements regarding safety and efficacy of product candidates, any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, forward-looking statements may contain the words
&#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will be,&#148; &#147;will continue,&#148; &#147;will result,&#148; &#147;seek,&#148;
&#147;could,&#148; &#147;may,&#148; &#147;might,&#148; or any variations of such words or other words with similar meanings. All forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their
entirety by the cautionary statements and risk factors set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus and set forth in our Form 10-K for the year ended December&nbsp;31, 2015 and subsequent Quarterly Reports on Form 10-Q
filed with the SEC. See &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; in this prospectus for information on how to access or obtain our reports filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given their inherent uncertainty, you should not place undue reliance on these forward-looking statements. You should read this prospectus and
the documents that we reference in this prospectus with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we do not undertake any obligation to update or revise any
forward-looking statements contained in this prospectus, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISK <A NAME="toc219508_4">
</A>FACTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves significant risks. Before making an investment decision, you should carefully
consider the risks described below, together with the information under &#147;Risk Factors&#148; in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and the other information incorporated by reference in this
prospectus. Some of these factors relate principally to our business and the industry in which we operate. Other factors relate principally to your investment in our common stock. If any of these risks were to occur, our business, financial
condition, results of operations, cash flows or prospects could be materially and adversely affected. In such case, you may lose all or part of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The risks and uncertainties described below and in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely affect our business and operations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Former Commercial Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. federal and state health care fraud and abuse and false claims laws and regulations, and we recently have been subpoenaed in
connection with marketing and promotional practices related to Abstral. Prosecutions under such laws have increased in recent years and we may become subject to such prosecutions or related litigation under these laws. If we have not fully complied
with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our former commercial operations are subject to various U.S. federal and
state fraud and abuse laws, including, without limitation, the federal False Claims Act, federal Anti-Kickback Statute, and the federal Sunshine Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians
for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the
U.S. Attorney&#146;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April&nbsp;28, 2016, a second superseding indictment was filed in the criminal case, which
added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#146; pharmacy as well as their ownership of our
stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#146; attorney&#146;s fees. To our knowledge, we are not a target or subject of that
investigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There also have been federal and state investigations of a company that has a product that
competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December&nbsp;16, 2015, we received a subpoena issued by the U.S.
Attorney&#146;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#146;s Office for the District
of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found
to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties,
damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any,
that these matters or any resulting legal or administrative proceedings may have on our business or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal
False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from, the federal government.&nbsp;<I>Qui tam</I>&nbsp;suits filed under the False Claims
Act can be brought by any individual on behalf of the government and such individuals, commonly known as &#147;relators&#148; or &#147;whistleblowers,&#148; may share in any amounts paid by the entity to the government in fines or settlement. The
frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of health care companies to have to defend such&nbsp;<I>qui tam</I>&nbsp;actions and pay substantial sums to settle such actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration,
directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal health care program such as the Medicare and Medicaid
programs. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal health care covered business, the statute has been violated.
The Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the health care industry. Penalties for violations of the federal Anti-Kickback
Statute include criminal penalties and civil and administrative sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal health care programs. An alleged violation of the Anti-Kickback Statute may be
used as a predicate offense to establish liability pursuant to other federal laws and regulations such as the federal False Claims Act. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the
referral of patients for health care items or services reimbursed by any source, not only Medicare and Medicaid programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal
Patient Protection and Affordable Care Act includes provisions expanding the ability of certain relators to bring actions that would have been dismissed under prior law. When an entity is determined to have violated the federal False Claims Act, it
may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. The Deficit Reduction Act of 2005 encouraged states to enact or modify their state false claims acts to be
at least as effective as the federal False Claims Act by granting states a portion of any federal Medicaid funds recovered through Medicaid-related actions. Most states have enacted state false claims laws, and many of those states included laws
including qui tam provisions. The federal Patient Protection and Affordable Care Act includes provisions known as the Physician Payments Sunshine Act, which requires manufacturers of drugs, biologics, devices and medical supplies covered under
Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data beginning in 2013 to the Centers for Medicare and Medicaid Services for subsequent public disclosures. Manufacturers must also
disclose investment interests held by physicians and their family members. Failure to submit the required information may result in civil monetary penalties of up to $1 million per year for knowing violations and may result in liability under other
federal laws or regulations. Similar reporting requirements have also been enacted on the state level in the U.S., and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of
interactions with health care professionals. In addition, some states such as Massachusetts and Vermont imposed an outright ban on certain gifts to physicians. These laws could affect our product promotional activities by limiting the kinds of
interactions we could have with hospitals, physicians or other potential purchasers or users of our system. Both the disclosure laws and gift bans also will impose administrative, cost and compliance burdens on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face product liability exposure and, if successful claims are brought against us, we may incur substantial liability if our insurance coverage for
those claims is inadequate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The commercial sale of our products after they are approved as well as the use of our products in
clinical trials exposes us to possible product liability claims. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA, if our products were sold to third
parties, or if our products are provided in clinical trials. Our products are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our products could result in injury
to a patient or even death. For example, because the placebo may have performed better than NeuVax in the PRESENT Trial, the use of NeuVax may have worsened the patient&#146;s condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Product liability claims may be brought against us by consumers, health care providers,
pharmaceutical companies or others selling or otherwise coming into contact with our products or generic versions of our products. If we cannot successfully defend ourselves against product liability claims we could incur substantial liabilities.
Because we have sold Abstral and Zuplenz and provided NeuVax as a study drug in the Present Trial, regardless of merit or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have obtained product
liability insurance coverage for commercial product sales with a $10 million per occurrence and a $10 million annual aggregate coverage limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or
losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts
or upon adequate terms to protect us against losses due to product liability. If we determine that it is prudent to increase our product liability coverage based on sales of our products, we may be unable to obtain this increased product liability
insurance on commercially reasonable terms or at all. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects, including side effects that may be less severe than those of our
products. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material adverse effect on our business,
results of operations, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and our third-party
manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers and suppliers activities involve the controlled storage, use and disposal of hazardous materials. We and our
manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials even after we sell or otherwise dispose of the products. In some cases, these hazardous
materials and various wastes resulting from their use will be stored at our contractors or manufacturers&#146; facilities pending use and disposal. We cannot completely eliminate the risk of contamination, which could cause injury to our employees
and others, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we expect that the safety
procedures utilized by our third-party contractors and manufacturers for handling and disposing of these materials will generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this will be the case or
eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources. We do not currently carry biological or hazardous waste
insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will continue to be responsible for certain liabilities and obligations related to Abstral and Zuplenz, and if unknown liabilities were to arise it
could have a material adverse effect on us. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our respective asset purchase agreements with Sentynl and Midatech, our future
obligations under our former agreements with Orexo AB and MonoSol have been assumed by Sentynl and Midatech, respectively, except that we will continue to be responsible for chargebacks, rebates, patient assistance and certain other product
distribution channel liabilities related to Abstral and Zuplenz for a specified period of time post-closing. We also will be responsible for any pre-closing liabilities and obligations related to Abstral and Zuplenz, including unknown liabilities,
and have agreed in the respective asset purchase agreements to indemnify Sentynl and Midatech for any breach of our representations, warranties and covenants in the respective asset purchase agreements up to a certain agreed to amount. We cannot
quantify these responsibilities to Sentanyl and Midatech, but if substantial unknown liabilities were to arise, it could have a material adverse effect on our financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Development Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
drug candidates may not receive regulatory approval or be successfully commercialized. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before they can be marketed, our products
in development must be approved by the FDA or similar foreign governmental agencies. The process for obtaining FDA approval is both time-consuming and costly, with no certainty of a successful outcome. Before obtaining regulatory approval for the
sale of any drug candidate, we must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Although our drug candidates have exhibited no serious
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse events, or SAEs, in the Phase 1 and 1/2 clinical trial, SAEs or other unexpected side effects may arising during further testing and development. A failure of any preclinical study or
clinical trial can occur at any stage of testing. The results of preclinical and initial clinical testing of these products may not necessarily indicate the results that will be obtained from later or more extensive testing. It also is possible to
suffer significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Phase 3 PRESENT clinical
trial has been stopped due to futility and though we are conducting an investigation of the causes for the failure of the clinical trial, we are not certain that the investigation will result in the reason(s) for the failure. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;27, 2016, the Independent Data Monitoring Committee conducting the pre-planned interim analysis of the PRESENT Trial recommended
that we stop the clinical trial because of futility. We are conducting an investigation of the causes of the failure of the trial, which may take a number of months. Once the investigation has been concluded, we may or may not know the reasons for
the failure of the clinical trial. As we are conducting the investigation, we have stopped any further dosing of the patients. The investigation may cause us to unblind the data of the clinical trial. Because we will be investigating the causes of
the failure of the clinical trial, the PRESENT Trial may no longer likely be considered a registrational clinical trial. Even if we determine the causes of the failure, NeuVax may never be approved for the treatment of patients with Node positive
HER2 negative breast cancer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products, GALE 301 and GALE 302 have the same mechanism of actions NeuVax and may not be a viable product to
prevent the recurrence of ovarian cancer or other types of cancers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">GALE 301/302, which have a similar mechanism of action as
NeuVax, may no longer be a viable product to prevent the recurrence of ovarian cancer or other types of cancer, depending upon the reasons for the causes of the failure of NeuVax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A number of different factors could prevent us from obtaining regulatory approval or commercializing our product candidates on a timely basis, or at
all. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the FDA or other applicable regulatory authorities, an Independent Data Safety Monitoring Board, or IDSMB, governing our
clinical trials, or an institutional review board, or IRB, which is an independent committee registered with and overseen by the U.S. Department of Health and Human Services, or HHS, that functions to approve, monitor and review biomedical and
behavioral research involving humans, may suspend clinical trials of a drug candidate at any time for various reasons, including if we or it believe the subjects or patients participating in such trials are being exposed to unacceptable health
risks. Among other reasons, adverse side effects of a drug candidate on subjects or patients in a clinical trial could result in the FDA or other regulatory authorities suspending or terminating the trial and refusing to approve a particular drug
candidate for any or all indications of use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials of a new drug candidate require the enrollment of a sufficient number of
patients, including patients who are suffering from the disease the drug candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, and delays in patient enrollment can result in
increased costs and longer development times than we expect at present. Patients who are enrolled at the outset of this standard of care also may eventually choose for personal reasons not to participate in the study. We also compete for eligible
patients with other breast cancer trials underway from time to time, and we may experience delays in patient enrollment due to the dependency of other large trials underway in the same patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials also require the review and oversight of IRBs, which approve and continually review clinical investigations to protect the
rights and welfare of human subjects. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical
investigation not subject to initial and continuing IRB review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, cancer vaccines are a relatively new form of
therapeutic treatment and a very limited number of such products have received regulatory approval. Therefore, the FDA or other regulatory authority may apply standards for approval of a new cancer vaccine that is different from past experience.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Numerous factors could affect the timing, cost or outcome of our drug development efforts, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties or delays in enrolling patients in our Phase 1/2 clinical trials of GALE-301 (folate binding protein (FBP) vaccine), our Phase 2 or possible phase 3 clinical trial of GALE-401 (anagrelide controlled
release) or other clinical trials in conformity with required protocols or projected timeline or in our other NeuVax clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties or delays in arranging for third parties to conduct clinical trials of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our drug candidates having very different chemical and pharmacological properties in humans than in laboratory testing and interacting with human biological systems in unforeseen, ineffective or harmful ways, and the
possibility that our previous Phase 1 or Phase 2 trials will not be indicative of our drug candidates&#146; performance in larger patient populations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disruption at our foreign clinical trial sites resulting from local social or political unrest or other geopolitical factors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effects of our drug candidates not being the desired effects or including undesirable side effects or the drug candidates having other unexpected characteristics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to our own or inability to generate statistically significant data confirming the efficacy of the
product being tested; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results obtained by other companies developing similar drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modification of the drug during testing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reallocation of our financial and other resources to other clinical programs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is possible
that none of the product candidates that we develop will obtain the appropriate regulatory approvals necessary for us to begin selling them or that any regulatory approval to market a product may be subject to limitations on the indicated uses for
which we may market the product. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the complexity of the drug candidate. Any analysis we
perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Any delay or failure in obtaining required approvals could have a material
adverse effect on our ability to generate revenue from the particular drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the length of time to develop the
product candidates as well as any regulatory delays in the development and regulatory approval process could cause the patent exclusivity to be unavailable or greatly reduced for each product candidate. The lack of patent exclusivity could have a
material adverse effect on our ability to generate revenue from the particular drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also subject to numerous foreign
regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval
described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not assure approval by regulatory authorities outside of the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent upon contract manufacturers for clinical supplies of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have the facilities or expertise to manufacture supplies of any of our product candidates for clinical trials. Accordingly, we are
dependent upon contract manufacturers for these supplies. There can be no assurance that we will be able to secure needed supply arrangements on reasonable terms, or at all. Our failure to secure these arrangements as needed could have a materially
adverse effect on our ability to complete the development of our product candidates or, if we obtain regulatory approval for our product candidates, to commercialize them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current plans call for the manufacture of our compounds by contract manufacturers offering research grade, Good Laboratory Practices grade
and Good Manufacturing Practices grade materials for preclinical studies (e.g., toxicology studies) and for clinical use. Certain of our product candidates are complex molecules requiring many synthesis steps, which may lead to challenges with
purification and scale-up. These challenges could result in increased costs and delays in manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NeuVax is administered in
combination with Leukine, a &#147;GM-CSF&#148; available in both liquid and lyopholyzed forms exclusively from Genzyme Corporation, or &#147;Genzyme,&#148; a subsidiary of Sanofi-Aventis. We will continue to be dependent on Genzyme for our supply of
Leukine in connection with the ongoing NeuVax and GALE-301/GALE-302 trials and the potential commercial manufacture of these programs. Any temporary interruptions or discontinuation of the availability of Leukine, or any determination by us to
change the GM-CSF used with NeuVax or GALE-301/GALE-302, may have a material adverse effect on our clinical trials and any commercialization of the assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to establish or maintain the third-party relationships that are necessary to develop or
potentially commercialize some or all of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to depend on collaborators, partners, licensees,
clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates, to manufacture our product candidates, and to conduct clinical trials for some or all of our product candidates. We cannot
guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to
successfully negotiate such agreements will depend on, among other things, potential partners&#146; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that we have
generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or
commercialize our product candidates. Under certain license agreements that we have already entered into, we have minimum dollar amounts per year that we are obligated to spend on the development of the technology we have licensed from our contract
partners and other obligations to maintain certain licenses. If we fail to meet this requirement under any of our licenses that contain such requirements or any other obligations under these licenses, we may be in breach of our obligations under
such agreement, which may result in the loss of the technology licensed. We cannot necessarily control the amount or timing of resources that our contract partners will devote to our research and development programs, product candidates or potential
product candidates, and we cannot guarantee that these parties will fulfill its obligations to us under these arrangements in a timely fashion. We may not be able to readily terminate any such agreements with contract partners even if such contract
partners do not fulfill its obligations to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may receive notices from third parties from time to time alleging that our
technology or product candidates infringe upon the intellectual property rights of those third parties. Any assertion by third parties that our activities or product candidates infringe upon its intellectual property rights may adversely affect our
ability to secure strategic partners or licensees for our technology or product candidates or our ability to secure or maintain manufacturers for our compounds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to competition and may not be able to compete successfully. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biotechnology industry, including the cancer immunotherapy market, is intensely competitive and involves a high degree of risk. We compete
with other companies that have far greater experience and financial, research and technical resources than us. Potential competitors in the U.S. and worldwide are numerous and include pharmaceutical and biotechnology companies, educational
institutions and research foundations, many of which have substantially greater capital resources, marketing experience, research and development staffs and facilities than us. Some of our competitors may develop and commercialize products that
compete directly with those incorporating our technology, introduce products to market earlier than our products or on a more cost effective basis. In addition, our technology may be subject to competition from other technology or methods developed
using techniques other than those developed by traditional biotechnology methods. Our competitors compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our
technology. We and our collaborators may face competition with respect to product efficacy and safety, ease of use and adaptability to various modes of administration, acceptance by physicians, the timing and scope of regulatory approvals,
availability of resources, reimbursement coverage, price and patent position, including the potentially dominant patent positions of others. An inability to successfully complete our product development could lead to us having limited prospects for
establishing market share or generating revenue from our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For patients with early stage breast cancer, adjuvant therapy is
often given to prevent recurrence and increase the chance of long-term disease free survival. Adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, radiation therapy, or combinations thereof. In addition, the HER2 targeted
drug trastuzumab (Herceptin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) may be given to patients with tumors with high expression of HER2 (IHC 3+), in the adjuvant setting which may be useful in treating breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are a number of cancer vaccines in development for breast cancer, including but not limited to Lapuleucel-T (Dendreon), and AE-37
(Antigen Express). While these development candidates are aimed at a number of different targets, and AE-37 has published data in the HER2 breast cancer patient population, there is no guarantee that any of the these compounds will not in the future
be indicated for treatment of low to intermediate HER2 breast cancer patients and become directly competitive with NeuVax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on
technologies we license, and if we lose the right to license such technologies or we fail to license new technologies in the future, our ability to develop new products would be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently are dependent on licenses from third parties for technologies relating to our product candidates. Our current licenses impose,
and any future licenses we enter into are likely to impose, various development, funding, royalty, diligence, sublicensing, insurance and other obligations on us. If our license with respect to any of these technologies is terminated for any reason,
the development of the products contemplated by the licenses would be delayed, or suspended altogether, while we seek to license similar technology or develop new non-infringing technology. The costs of obtaining new licenses are high. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks associated with operating in foreign countries could materially adversely affect our product
development. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may conduct future studies in countries outside of the U.S. Consequently, we may be subject to risks related to
operating in foreign countries. Risks associated with conducting operations in foreign countries include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment,
immigration and labor laws for employees living or traveling abroad; foreign taxes, including withholding of payroll taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, there may be political instability, including war, terrorism, riots, civil insurrection or social unrest, and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease, which could seriously harm the
progress of our clinical trials at sites in particular foreign countries or regions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Financial Position and Capital Requirements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain sufficient financing, and may not be able to develop our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had cash and cash equivalents of approximately $19.6 million as of June&nbsp;30, 2016. In addition, we had approximately $24 million of
restricted cash that is reserved for a lender who has the option to redeem all, or part, of such amount within 30 trading days of our public announcement on June&nbsp;29, 2016, of the discontinuation of the Phase 3 PRESENT Trial upon the IDMC&#146;s
recommendation on June&nbsp;27, 2016. As of the date of this prospectus, the lender has not redeemed the approximately $24 million in full or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had no revenue for the quarter ending June&nbsp;30, 2016, and our cash burn from operations for the quarter ending June&nbsp;30, 2016 was
approximately $13 million. In addition, we paid off our loan with Oxford Finance LLC for a total of $3.1 million. The Company has stopped the PRESENT Trial and is running an investigation that is estimated to cost between $250,000 and $500,000 over
the next three months. Depending on the outcome of the investigation, the estimated cost to close out the PRESENT Trial will be between $4 million to $7 million. On July&nbsp;1, 2016, we paid $2.3 million for the securities class action settlement.
We believe that our existing cash and cash equivalents together with the net proceeds we received on July 13, 2016 from selling 28,000,000 shares of common stock and 14,000,000 warrants (the &#147;July Financing&#148;) should be sufficient to fund
our operations for at least six months. This projection is based on our current planned operations, stopping the PRESENT Trial and investigation of the causes of the failure of such clinical trial, anticipated payments for defense costs for the
cooperation and discussions with the staff in the SEC investigation and other governmental investigations, and is subject to changes in our plans and uncertainties inherent in our business. We will need to seek to replenish our existing cash and
cash equivalents prior to the end of 2016. We also have funding available under our purchase agreement with Lincoln Park Capital Fund, LLC and sales agreements with MLV&nbsp;&amp; Co. and Maxim Group LLC described in the previously filed
prospectuses, but there is no guarantee that such funding will be available to us on favorable terms or will be sufficient to meet all of our future funding needs. Additionally, in connection with the July Financing, we have agreed not to issue any
shares of our common stock (including under our purchase agreement with Lincoln Park Capital Fund, LLC and under our sales agreements with MLV&nbsp;&amp; Co. and Maxim Group LLC) for a period of 75 days from the date of the closing of the July
Financing. At our annual meeting of stockholders adjourned on July 15, 2016, our stockholders approved an increase in our authorized common stock from 275,000,000 to 350,000,000. We are not able to predict whether these additional shares will be
sufficient based upon our current stock price to meet the Company&#146;s ongoing financing requirements to maintain the Company&#146;s operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we fail to obtain additional future funding when needed, we could be forced to scale back or terminate our operations, or to seek to merge
with or to be acquired by another company. We may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to continue as a going concern may result in our
common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to continue to incur significant research and development expenses, which may make it difficult
for us to attain profitability, and may lead to uncertainty about our ability to continue as a going concern. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Substantial funds
were expended to develop our technologies and product candidates, and additional substantial funds will be required for further preclinical testing and clinical trials of our product candidates, and to manufacture and market any products that are
approved for commercial sale. Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to
generate enough revenue, even if we are able to commercialize any of our product candidates, to become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event that we
are unable to achieve or sustain profitability or to secure additional financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to our ability to continue as a going concern. Any such inability to
continue as a going concern may result in our common stock holders losing their entire investment. There is no guaranty that we will become profitable or secure additional financing. Our financial statements contemplate that we will continue as a
going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated working capital needs, the acceleration or modification of our
expansion plans, increased expenses, potential acquisitions or other events will all affect our ability to continue as a going concern. Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt
or equity, which may have an adverse effect on our security holders or may otherwise adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we raise funds
through the issuance of debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation. In such event, there is a possibility
that once all senior claims are settled, there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance of additional equity, whether through private placements or additional public
offerings, such an issuance would dilute your ownership in us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The terms of debt securities may also impose restrictions on our
operations, which may include limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to
satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may
have difficulty evaluating our business, and our historical financial information may not be representative of our future results. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recently announced the recommendation to stop the PRESENT Trial for futility and we are investigating the reasons for such failure. As a
result, we will focus our resources on our pipeline of other product candidates. As a result, we will have no recurring revenues unless and until we are able to obtain marketing approval of one or more of our other product candidates and our
historical financial information may not be representative of our future results. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to comply with our reporting and other
requirements under federal securities laws. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a publicly traded company, we are subject to the reporting requirements of the
Securities Exchange Act of 1934, as amended, or the &#147;Exchange Act,&#148; and the Sarbanes-Oxley Act of 2002, or the &#147;Sarbanes-Oxley Act.&#148; In addition, the Exchange Act requires that we file annual, quarterly and current reports. Our
failure to prepare and disclose this information in a timely manner could subject us to penalties under federal securities laws, expose us to lawsuits and restrict our ability to access financing. The Sarbanes-Oxley Act requires that we, among other
things, establish and maintain effective internal controls and procedures for financial reporting. From time to time we evaluate our existing internal controls in light of the standards adopted by the Public Company Accounting Oversight Board. It is
possible that we or our independent registered public accounting firm may identify significant deficiencies or material weaknesses in our internal control over financial reporting in the future. Any failure or difficulties in implementing and
maintaining these controls could cause us to fail to meet the periodic reporting obligations or result in material misstatements in our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404 of the Sarbanes-Oxley Act requires annual management and independent auditor assessments of the effectiveness of our internal
control over financial reporting. Our failure to satisfy the requirements of Section&nbsp;404 on a timely basis could result in the loss of investor confidence in the reliability of our financial statements, which in turn could have a material
adverse effect on our business and our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain and enforce patent rights or other intellectual property rights that cover our product candidates and that are of sufficient
breadth to prevent third parties from competing against us. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success with respect to our product candidates will depend in
part on our ability to obtain and maintain patent protection in the U.S. and abroad, to preserve our trade secrets, and to prevent third parties from infringing upon our proprietary rights. Our patents and patent applications, however, may not be
sufficient to provide protection for NeuVax or our other products and product candidates against commercial competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The active
peptide found in NeuVax, the E75 peptide, has been known and studied for many years. We have one issued U.S. patent, US 6,514,942, covering the composition of matter of the E75 peptide, which expired in mid-2015, prior to any potential
commercialization of NeuVax. We do not have and will not be able to obtain any composition of matter patent protection for E75, the active peptide in NeuVax. We also have a license from The Henry M. Jackson Foundation to issued U.S., European,
Japanese, Korean, Mexican and Australian method of use patents, which expire in 2028, that are directed to a method of inducing immunity against breast cancer recurrence by administering a composition comprising the E75 peptide to patients who have
both an immunohistochemistry (IHC) rating of 1+ or 2+ for HER2/neu protein expression, as well as a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression. The license further includes an issued U.S.
method of use patent directed to a method of inducing immunity against recurrence of any HER2/neu expressing tumors by administering the E75 peptide to patients with tumors having a FISH rating of less than about 2.0 for HER2/neu gene expression; an
allowed U.S application which includes claims to the use of E75 to reduce the risk of cancer recurrence, including bone only recurrence; and pending applications with similar claims in a number of foreign jurisdiction, all of which expire in 2028.
Also included in the license is a method of use patent, which expires in 2026, that is directed to the use of NeuVax in combination with Herceptin&reg; to treat any HER2/neu expressing cancer. Thus, our method of use patents may not prevent
competitors from seeking to develop and market NeuVax for use in cancer patients who do not meet these criteria. If any such alternative uses were approved, this could lead to off-label use and price erosion for our NeuVax product. We may seek FDA
approval for use of NeuVax to treat cancer patients who fall outside the claimed IHC and FISH ranges and for other cancers as well. Although we are pursuing additional patent protection for NeuVax through pending patent applications, we may not be
able to obtain additional patent protection that would provide us with a significant commercial advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Anagrelide hydrochloride, the
sole active pharmaceutical ingredient, or API, in GALE-401, has been approved for many years and, thus, it is not possible to obtain composition of matter patents that cover anagrelide hydrochloride. As a result, competitors who obtain the requisite
regulatory approval can offer products with the same 43 API as GALE-401, so long as the competitors do not infringe any formulation patents that we may have or may obtain or license, if any. The only patent protection that we have or are likely to
obtain covering GALE-401 are patents relating to specific formulations, methods using these formulations, and methods of manufacturing and packaging. We have an issued U.S. Patent, which expires in 2020, covering methods of using anagrelide to
reduce platelet count in patients subject to veno-occlusive events. We have granted patents in the U.S., United Kingdom and Japan, which expire in 2029, covering controlled release formulations of anagrelide and methods of use. We also are
prosecuting pending patent applications in other territories including, but not limited to, the U.S. Europe, India and Japan, which may not issue prior to any potential commercialization of GALE-401. We may seek FDA approval for use of GALE-401 to
treat patients with myeloproliferative neoplasms that include several hermatological disorders. Although we are pursuing additional patent protection for GALE-401 through pending patent applications, we may not be able to obtain additional patent
protection that would provide us with a significant commercial advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The active peptides found in GALE-301 and GALE-302 are derived
from Folate Binding Protein. One of the active peptides, E39, has been known and studied for many years. The other active peptide, GALE-302, is a derivative of E39. We have a license from The Henry M. Jackson Foundation to issued and granted patents
in the U.S., Europe, Canada, and Japan, covering composition of matter for the E39 derivative peptides, including GALE-302, alone and in combination with E39, as well as the use of these compositions for the treatment of cancer. These patents are
expected to expire in 2022, prior to any potential commercialization of GALE-301. We do not have and will not be able to obtain any composition of matter patent protection for the E39 peptide in any territory. The license we have from The Henry M.
Jackson Foundation grants us the right to develop and market GALE-301 for any use, including methods of treating cancer, our patents may not prevent competitors from seeking to develop and market the E39 peptide alone. If any such alternative uses
of compositions containing the E39 peptide were approved, this could lead to off label use and price erosion for GALE-301. We may seek FDA approval for use of GALE-301, alone or in combination with GALE-302, to treat cancer patients with ovarian and
endometrial cancers and for other cancers, as well. Although we are pursuing additional patent protection for GALE-301 and the combination of GALE-301 and GALE-302 through pending patent applications, we may not be able to obtain additional patent
protection that would provide us with a significant commercial advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and
factual questions. Accordingly, rights under any patents we have or may obtain or license may not provide us with sufficient protection for our commercial product and product candidates to afford a commercial advantage against competitive products
or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Nor can we guarantee that the
claims of these patents will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or in the interpretations of patent laws in the U.S. or abroad may diminish the value of our intellectual
property. In addition, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to the U.S. patent law. These include provisions that
affect the way patent applications will be prosecuted and may also affect patent litigation. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act, in
particular the first-to-file provision and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement of or defense of our issued patents, all of which could have a
material adverse effect on our business and financial condition. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we intend to take actions reasonably necessary to enforce our patent rights, we may not be able to detect infringement of our own or
in-licensed patents, which may be especially difficult for methods of manufacturing or formulation products, and we depend, in part, on our licensors and collaborators to protect a substantial portion of our proprietary rights. In addition, third
parties may challenge our in-licensed patents and any of our own patents that we may obtain, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to enforce or
defend intellectual property rights is very complex, expensive, and may divert our management&#146;s attention from our core business and may result in unfavorable results that could adversely affect our ability to prevent third parties from
competing with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If another party has reason to assert a substantial new question of patentability against any of our claims in our own
and in-licensed patents, the third party can request that the patent claims be reexamined, which may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential infringement suits and, interference and
reexamination proceedings, we may become a party to patent opposition proceedings where either the patentability of the inventions subject of our patents are challenged, or we are challenging the patents of others. The costs of these proceedings
could be substantial, and it is possible that such efforts would be unsuccessful. As the medical device, biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our commercial product
and/or product candidates infringe their patent rights. If a third-party is patents were found to cover our commercial product and product candidates, proprietary technologies or its uses, we or our collaborators could be enjoined by a court and
required to pay damages and could be unable to continue to commercialize our products or use our proprietary technologies unless we or it obtained a license to the patent. A license may not be available to us or our collaborators on acceptable
terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief, which could prohibit us from making, using or selling our commercial product and product candidates pending a trial
on the merits, which could be years away. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Proprietary trade secrets and unpatented know-how are also very important to our business.
Although we have taken steps to protect our trade secrets and unpatented know-how, by entering into confidentiality agreements with third parties, and proprietary information and invention agreements with certain employees, consultants and advisors,
third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our licensors, collaborators and suppliers. There can be no assurance that binding
agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are
independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time consuming, and the outcome is unpredictable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged
trade secrets of their other clients or former employers. As is common in the biotechnology and pharmaceutical industry, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Moreover, we engage the services of consultants to assist us in the development of our commercial product and product candidates, many of whom were previously employed at or may have previously been or are currently providing
consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these types of claims. Even if we are successful in defending against any such claims, any
such litigation would likely be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may face competition sooner than expected after the expiration of our composition of
matter patent protection for such products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our composition of matter patents for many of our product candidates have expired or
will expire prior to any product approval. We intend to seek data exclusivity or market exclusivity for our NeuVax as well as our GALE-301 and GALE-302 product candidates provided under the Federal Food, Drug and Cosmetic Act, or FDCA, and similar
laws in other countries. We believe that these product candidates will qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which was enacted as part of the Patient Protection and
Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA) enacted in March 2010. Under the BPCIA, an application for a biosimilar product or biologics license
application (BLA) cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for
the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as
&#147;interchangeable&#148; based on its similarity to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the
FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological product candidates. There is also a risk that the U.S. Congress could amend the BPCIA to shorten this exclusivity period as proposed
by President Obama, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any
reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our product candidates are not considered biologics that would qualify for exclusivity under the BPCIA, they may be eligible for market
exclusivity as drugs under the FDCA. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has
not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug
application, or ANDA, or a 505(b)(2) NDA, submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be
submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths of an existing drug.
This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if, as we expect, GALE-301 and GALE-302 are considered to be reference products eligible for 12 years of exclusivity under the BPCIA or
five years of exclusivity under the FDCA, another company could market competing products if the FDA approves a full BLA or full NDA for such product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of the products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some countries outside of the U.S., peptide vaccines,
such as GALE-301 and GALE-302, are regulated as chemical drugs rather than as biologics and may or may not be eligible for non-patent exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we have received orphan drug designation for both GALE-301, as well as GALE-301and GALE-302, there is no guarantee that the drugs
will be successfully approved by the FDA, that they will be commercially successful in the marketplace, or that another drug will not be approved for the same indication ahead of our drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price and trading volume of our common stock may be volatile. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock has exhibited substantial volatility recently. Between July&nbsp;13, 2015 and July&nbsp;13, 2016, the
sale price of our common stock as reported on The NASDAQ Capital Market ranged from a low of $0.28 to a high of $2.49. The market price of our common stock could continue to fluctuate significantly for many reasons, including the following factors:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reports of the results of our clinical trials regarding the safety or efficacy of our product candidates and surrogate markers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of regulatory developments or technological innovations by us or our competitors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of business or strategic transactions such as our recent sales of our marketed products and discontinuation of our commercial operations, or our success in doing so; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of legal or regulatory actions against us or any adverse outcome of any such actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our relationship with our licensors, licensees and other strategic partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our quarterly operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments in patent or other technology ownership rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern regarding the safety of our Abstral product or our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">government regulation of drug pricing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general changes in the economy, the financial markets or the pharmaceutical or biotechnology industries. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Factors beyond our control may also have an impact on the price of our stock. For example, to the extent that other companies within our
industry experience declines in their stock prices, our stock price may decline as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are, and in the future may be, subject to legal or
administrative actions that could adversely affect our financial condition and our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2015, we agreed
in principle to resolve and settle the consolidated shareholder derivative action,&nbsp;<I>In re Galena Biopharma, Inc. Derivative Litigation</I>, Civil Action No.&nbsp;3:14-cv-00382-SI against us and certain of our current and former officers and
directors. Following the hearing on June&nbsp;23, 2016, on June&nbsp;24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in&nbsp;<I>In re Galena Biopharma, Inc. Derivative Litigation</I>, granting final
approval to the settlement. On the same day, the court also issued an opinion and order awarding attorney&#146;s fees of $4.5 million plus costs, which will be paid by our insurance carriers. The settlement includes a payment of $15 million in cash
by our insurance carriers, which we will use to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance
measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the individual defendants in connection with the allegations made in the
consolidated federal derivative actions and state court derivative actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2015, we also agreed in principal to
resolve and settle the securities putative class action lawsuit,<I>&nbsp;</I><I>In re Galena Biopharma, Inc. Securities Litigation</I>, Civil Action No.&nbsp;3:14-cv-00367-SI, against us, certain of our current and former officers and directors and
other defendants in the United States District Court for the District of Oregon. Following the hearing on June&nbsp;23, 2016, on June&nbsp;24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment
in&nbsp;<I>In re Galena Biopharma, Inc. Securities Litigation</I>, granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney&#146;s fees of $4.5 million plus costs, which is paid out of
the settlement funds. The agreement provides for a settlement payment of $20 million to the class and the dismissal of all claims against us and the other defendants in connection with the consolidated federal securities class actions. Of the $20
million settlement payment to the class, $16.7 million was paid by our insurance carriers and $2.3 million in cash was paid by us on July&nbsp;1, 2016, along with $1 million in shares of our common stock (480,053 shares) was paid by us on
July&nbsp;6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and
other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians
for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the
U.S. Attorney&#146;s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April&nbsp;28, 2016, a second superseding indictment was filed in the criminal case, which
added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians&#146; pharmacy as well as their ownership of our
stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees&#146; attorney&#146;s fees. To our knowledge, we are not a target or subject of that
investigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There also have been federal and state investigations of a company that has a product that
competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December&nbsp;16, 2015, we received a subpoena issued by the U.S.
Attorney&#146;s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney&#146;s Office for the District
of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found
to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties,
damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any,
that these matters or any resulting legal or administrative proceedings may have on our business or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Litigation is
inherently uncertain. We have incurred and may continue to incur substantial unreimbursed legal fees and other expenses in connection with these or other legal and regulatory proceedings that may not qualify for coverage under, or may exceed the
limits of, our applicable directors and officers liability insurance policies and could have a material adverse effect on our financial condition, liquidity, and results of operations. These matters also may distract the time and attention of our
officers and directors or divert our other resources away from our ongoing development programs. An unfavorable outcome in any of these matters could damage our business and reputation or result in additional claims or proceedings against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our common stock is currently trading at prices less than $1.00, which is the minimum bid price requirement under NASDAQ&#146;s continued listing
standards. If our common stock continues to trade at such prices, our common stock may be subject to delisting from the NASDAQ Capital Market. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The continued listing requirements of the NASDAQ Capital Market require that the closing bid price of our common stock not be less than
$1.00.&nbsp;Following our announcement on June 29, 2016, that we had stopped our PRESENT trial, the closing bid price of our common stock has been less than $1.00.&nbsp;If the closing bid price of our common stock remains under $1.00 for a period of
at least 30 consecutive trading days, we expect to receive a letter from NASDAQ advising us that we are not in compliance with its continued listing requirements under NASDAQ Listing Rule 5502(a)(2).&nbsp;In accordance with Nasdaq Listing Rule
5810(c)(3)(A), we would then have 180 calendar days to regain compliance with the $1.00 minimum bid price requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of our is at least $1.00 per
share for a minimum of ten consecutive trading days during this initial 180-day compliance period. If compliance is not achieved within the 180-day period, NASDAQ would provide written notification to us that our common stock is subject to
delisting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event that we fail to regain compliance with NASDAQ continued listing standards by the expiration of the applicable
cure period or any extension period, NASDAQ will commence suspension and delisting procedures with respect to our common stock, which could impair the value of your investment. If our common stock is delisted from NASDAQ Capital Market in the
future, such securities may be traded over-the-counter on the &#147;pink sheets.&#148; Such alternative market, however, is generally considered to be less efficient than, and not as broad as, NASDAQ. Accordingly, delisting of our common stock from
NASDAQ could have a significant negative effect on the trading volume, liquidity and market price of our common stock. In addition, the delisting of our common stock could adversely affect our ability to raise capital on terms acceptable to us or at
all and could reduce the number of investors willing to hold or acquire our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of substantial amounts of our common stock,
or the possibility that such sales could occur, could adversely affect the market price of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future sales in the
public market of shares of our common stock, including shares referred to in the foregoing risk factors or shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the
market price of our common stock or make it difficult for us to raise additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2016, we had reserved for
issuance 12,000,552 shares of our common stock issuable upon the exercise of outstanding stock options at a weighted-average exercise price of $2.59 per share and 35,775,656 shares of our common stock issuable upon the exercise of outstanding
warrants at a weighted-average exercise price of $1.84 per share. Upon exercise of these options and warrants, the underlying shares may be resold into the public market. In the case of outstanding options and warrants that have exercise prices that
are below the market price of our common stock from time to time, our stockholders would experience dilution upon the exercise of these options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our outstanding warrants may result in dilution to our stockholders. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our outstanding April 2011 warrants to purchase a total of 615,398 shares of common stock as of March&nbsp;31, 2016 at a current exercise
price of $0.65 per share contain so-called full-ratchet anti-dilution provisions. Our outstanding March 2010 and December 2012 warrants to purchase 25,000 shares and 3,031,311 shares, respectively, of common stock as of March&nbsp;31, 2016 at
exercise prices of $1.92 and $1.75, respectively, per share contain so-called weighted-average anti-dilution provisions. These anti-dilution provisions may be triggered by the issuance of the shares being offered hereby or upon any future issuance
by us of shares of our common stock or common stock equivalents at a price per share below the then-exercise price of the warrants, subject to some exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that these anti-dilution provisions are triggered in the future, we would be required to reduce the exercise price of all of the
warrants on either a full-ratchet or weighted-average basis, which would have a dilutive effect on our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may issue preferred stock
in the future, and the terms of the preferred stock may reduce the value of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to
5&nbsp;million shares of preferred stock in one or more series. Our board of directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue preferred stock, it could affect stockholder
rights or reduce the market value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights,
sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions of our amended
and restated certificate of incorporation and amended and restated bylaws and provisions of Delaware law could delay or prevent a change of control. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or
prevent a merger or other change of control that stockholders may consider favorable or may impede the ability of the holders of our common stock to change our management and may be constrained by other contractual agreements with third parties.
These provisions of our amended and restated certificate of incorporation and amended and restated bylaws, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide our board of directors into three classes, with members of each class to be elected for staggered three-year terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the right of security holders to remove directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholders from acting by written consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulate how stockholders may present proposals or nominate directors for election at annual meetings of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue preferred stock in one or more series, without stockholder approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or
are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation such as our company shall not engage in any business combination with that corporation, including by merger, consolidation or
acquisitions of additional shares for a three-year period following the date on which that person or its affiliate crosses the 15% stock ownership threshold.&nbsp;Section&nbsp;203 could operate to delay or prevent a change of control of our company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never declared or paid cash dividends on our capital stock and we do not anticipate paying cash dividends in the foreseeable future.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business requires significant funding. We currently plan to invest all available funds and future earnings in the development
and growth of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future, and are prohibited by the terms of our outstanding indebtedness from paying dividends on any common stock, except with the
prior consent of our lenders. As a result, capital appreciation, if any, of our common stock will be our stockholders&#146; sole source of potential gain for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of our outstanding indebtedness may inhibit potential acquirers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are prohibited by the terms of our outstanding indebtedness from disposing of any of our business or property, except with the consent of
our lenders or if we were to prepay the outstanding indebtedness and related fees in accordance with the loan security agreement. Our outstanding indebtedness may inhibit potential acquirers or other interested parties from seeking to acquire all or
a part of our business or assets, and there is no assurance that our lenders would consent to any proposed future transaction that might be beneficial to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>USE OF PRO<A NAME="toc219508_5"></A>CEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to shares of our common stock that may be offered and sold from time to time by the selling stockholders. We will
receive no proceeds from the sale of shares of common stock by the selling stockholders in this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLING S<A NAME="toc219508_6">
</A>TOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling stockholders are offering under this prospectus up to 3,658,012 shares of our common stock. The selling
stockholders may, from time to time, offer and sell pursuant to this prospectus any or all of the shares offered hereby. The selling stockholders may sell some, all or none of its shares. We do not know how long the selling stockholders will hold
the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale of any of the shares or the exercise of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the selling stockholders and the shares that it may offer and sell from time to time under
this prospectus. The table is prepared based on information supplied to us by the selling stockholders, and reflects their holdings as of July 22, 2016. None of the selling stockholders, nor any affiliate of a selling stockholder, has held a
position or office, or had any other material relationship, with us or any of our predecessors or affiliates. Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act. The percentage of shares
beneficially owned prior to the offering is based on 210,843,953 shares of our common stock actually outstanding as of July 22, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman"><B>Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Beneficially</B><br><B>Owned&nbsp;Before&nbsp;this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Outstanding</B><br><B>Shares</B><br><B>Beneficially</B><br><B>Owned&nbsp;Before&nbsp;this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;of&nbsp;Outstanding<BR>Shares&nbsp;Offered&nbsp;by<BR>Selling&nbsp;Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of</B><br><B>Outstanding</B><br><B>Shares</B><br><B>Beneficially</B><br><B>Owned&nbsp;After&nbsp;this</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Barber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel DiPietro</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">975,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Wyckoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">859,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">859,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Liatos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">505,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">505,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Glidden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hosie Kenneth Riley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTALS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,658,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Denotes less than 1%. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLAN OF D<A NAME="toc219508_7"></A>ISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each selling stockholder of the shares offered hereby and any of their pledgees, assignees and successors-in-interest may, from time to time,
sell any or all of their securities covered hereby on the NASDAQ Capital Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions.&nbsp;These sales may be at fixed or negotiated
prices.&nbsp;A Selling Stockholder may use any one or more of the following methods when selling securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary brokerage transactions and transactions in which the <FONT STYLE="white-space:nowrap">broker-dealer</FONT> solicits purchasers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">block trades in which the <FONT STYLE="white-space:nowrap">broker-dealer</FONT> will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchases by a <FONT STYLE="white-space:nowrap">broker-dealer</FONT> as principal and resale by the <FONT STYLE="white-space:nowrap">broker-dealer</FONT> for its account; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exchange distribution in accordance with the rules of the applicable exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">privately negotiated transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">settlement of short sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in transactions through <FONT STYLE="white-space:nowrap">broker-dealers</FONT> that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a combination of any such methods of sale; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other method permitted pursuant to applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell
securities under Rule 144 under the Securities Act, if available, rather than under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Broker-dealers</FONT> engaged by the selling stockholders may arrange for other <FONT
STYLE="white-space:nowrap">brokers-dealers</FONT> to participate in <FONT STYLE="white-space:nowrap">sales.&nbsp;Broker-dealers</FONT> may receive commissions or discounts from the selling stockholders (or, if any
<FONT STYLE="white-space:nowrap">broker-dealer</FONT> acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the selling stockholders may
enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume.&nbsp;The selling stockholders may also sell securities
short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities.&nbsp;The selling stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions
received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholders has informed the Company that it
does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities.&nbsp;The Company has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities,
including liabilities under the Securities Act.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because selling stockholders may be deemed to be &#147;underwriters&#148; within the
meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under
the Securities Act may be sold under Rule 144 rather than under this prospectus. The selling stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the
selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold
by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144
under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.&nbsp;The resale securities will be sold
only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in
the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period,
as defined in Regulation M, prior to the commencement of the distribution.&nbsp;In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M,
which may limit the timing of purchases and sales of the common stock by the selling stockholders or any other person.&nbsp;We will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a
copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDE<A NAME="toc219508_8"></A>ND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business requires significant funding. We currently plan to invest all available funds and any future earnings in our business and do not
anticipate paying any cash dividends on our common stock in the foreseeable future. We currently are prohibited by the terms of our outstanding indebtedness from paying dividends on our common stock, except with the prior consent of our lenders.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF<A NAME="toc219508_9"></A> CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary of the terms of our securities is subject to and qualified by reference to our amended and restated certificate of
incorporation and our restated bylaws, copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information&#148; below for directions on obtaining these documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 355,000,000 shares, which includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">350,000,000 shares of common stock, par value $0.0001 per share, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,000,000 shares of preferred stock, par value $0.0001 per share. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;22, 2016,
there were 210,843,953 shares of common stock outstanding and no shares of preferred stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders.
Common stockholders are not be entitled to cumulative voting in the election of directors by our certificate of incorporation. This means that the holders of a majority of the shares voted will be able to elect all of the directors then standing for
election. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the
amounts that our board of directors may determine from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or winding-up, the holders of our
common stock will be entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any series of capital stock ranking senior to the common stock upon liquidation. Holders of common stock have
no preemptive or conversion rights or other subscription rights. There will be no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and nonassessable, and the shares of common
stock to be issued under this prospectus, when they are paid for, will be fully paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders, to
issue from time to time any of the authorized shares of preferred stock in one or more series without stockholder approval. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers,
qualifications, and special or relative rights or privileges as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The authority possessed by our board to issue preferred stock could potentially be used to discourage attempts by third parties to obtain
control of our company through a merger, tender offer, proxy contest or otherwise by making such attempts more difficult or more costly. Our board may issue preferred stock with voting rights or conversion rights that, if exercised, could adversely
affect the voting power of the holders of common stock. There are no current agreements or understandings with respect to the issuance of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Restated Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain
provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and
inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential
ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging such proposals, including proposals that are priced above the then-current market value of our common stock, because, among other reasons, the
negotiation of such proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue, without further action by the stockholders, up to 5,000,000 shares of undesignated preferred stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specify that special meetings of our stockholders can be called only by our board of directors, the chairman of the board or the chief executive officer; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that our board of directors will be classified, with directors serving staggered three-year terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that directors may be removed only for cause and may only be removed for cause only by the holders of 75% of our outstanding capital stock entitled to vote generally in the election of directors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for a 75% vote of stockholders to amend our amended and restated bylaws, unless the amendment has been approved by a majority of our directors who are not affiliated or associated with any person or entity
holding 10% or more of the voting power of our outstanding capital stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested
stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1)&nbsp;shares owned by persons who are directors and also officers and
(2)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to
the &#147;interested stockholder.&#148; Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15%
or more of a corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that
Section&nbsp;203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of common stock held by our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our amended and restated bylaws could have the effect of
discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions
may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on
The NASDAQ Capital Market under the symbol &#147;GALE.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEGAL <A NAME="toc219508_11"></A>MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fredrikson &amp; Byron P.A., Minneapolis, Minnesota, has rendered an opinion with respect to the validity of the shares of common stock
offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXP<A NAME="toc219508_12"></A>ERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Company as of December&nbsp;31, 2015 and 2014, and for each of the three years in the period
ended December&nbsp;31, 2015, and the effectiveness of internal control over financial reporting of the Company as of December&nbsp;31, 2015, have been incorporated by reference herein in reliance upon the reports of Moss Adams LLP, independent
registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WHERE YOU CAN FIN<A NAME="toc219508_13">
</A>D MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC
filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file
electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Room 1580, Washington D.C. 20549. You may also obtain copies of these documents at prescribed
rates by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCORPORATION OF CERTA<A NAME="toc219508_14"></A>IN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Reports on Form 10-K and Form 10-K/A for the year ended December&nbsp;31, 2015, which was filed on March&nbsp;10, 2016, and amended on March&nbsp;11, 2016,&nbsp;April&nbsp;15, 2016 and April&nbsp;29, 2016,
respectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2016, which was filed on May&nbsp;10, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K, which were filed on January&nbsp;7, 2016,&nbsp;February&nbsp;16, 2016,&nbsp;February&nbsp;25, 2016,&nbsp;March&nbsp;10, 2016,&nbsp;April&nbsp;7, 2016,&nbsp;April&nbsp;26,
2016,&nbsp;May&nbsp;10, 2016,&nbsp;June&nbsp;28, 2016, June&nbsp;29, 2016, July 8, 2016, July&nbsp;12, 2016, July&nbsp;18, 2016 and July 18, 2016, respectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our definitive Proxy Statement on Schedule 14A filed on June&nbsp;3, 2016, in connection with the 2016 annual meeting of stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A (File No.&nbsp;001-33958) filed pursuant to Section&nbsp;12 of the Exchange Act, as amended from time to time. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all additional documents that we file with the SEC under the terms of
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 that are made after the date of this prospectus and before the termination of the offering of securities offered by this prospectus. We are not, however, incorporating, in
each case, any documents or information that we are deemed to furnish and not file in accordance with SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You may request a copy
of any of the documents incorporated by reference into this prospectus, at no cost, by writing or telephoning us at the following address: Galena Biopharma, Inc., 2000 Crow Canyon Place, Suite&nbsp;380, San Ramon, California 94583, Attention:
Investor Relations, Phone: (855)&nbsp;855-4253. We will not send exhibits to any documents, unless the exhibits are specifically incorporated by reference into the document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g219508bcpg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>3,658,012 Shares of Common Stock </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016.
</B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Expenses of Issuance and Distribution </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses to be paid in
connection with the offering of securities described in this registration statement. All amounts shown are estimates, except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Indemnification of Directors and Officers. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General
Corporation Law provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative, other than an action by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation or is or was serving at the corporation&#146;s request as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#146; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
the person in connection with the action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. The power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of expenses, including attorneys&#146;
fees but excluding judgments, fines and amounts paid in settlement, actually and reasonably incurred by the person in connection with the defense or settlement of the action or suit if the person acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that a court of competent jurisdiction shall determine that such indemnity is proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(g) of the Delaware General Corporation Law provides that a corporation shall have the power to purchase and maintain
insurance on behalf of its officers, directors, employees and agents, against any liability asserted against and incurred by such persons in any such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the General Corporation Law of the State of Delaware provides that a corporation may eliminate or limit the personal
liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the General
Corporation Law of the State of Delaware, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. No such provision shall eliminate or limit the liability of a director for any act or omission occurring prior
to the date when such provision becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation provides that our directors
shall not be liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent that the exculpation from liabilities is not permitted under the Delaware General Corporation Law as in effect at the
time such liability is determined. In addition, our Amended and Restated Certificate of Incorporation provides that we shall, to the maximum extent permitted by the General Corporation Law of the State of Delaware, indemnify each person who was or
is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was, or has agreed to become, our
director or officer, or is or was serving, or has agreed to serve, at our request, as a director, officer, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, including
any employee benefit plan (all such persons being referred to hereafter as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such action, suit or proceeding and any appeal therefrom, if he acted in good faith and in a manner he reasonably believed to
be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, and that we shall not indemnify an Indemnitee seeking indemnification in connection
with any action, suit, proceeding, claim or counterclaim, or part thereof, initiated by the Indemnitee unless the initiation thereof was approved by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation also provides that any indemnification
under the preceding paragraph (unless ordered by a court) shall be made by us only as authorized in the specific case upon a determination that indemnification is proper in the circumstances because such person has either met the applicable standard
of conduct set forth in this paragraph and that the amount requested has been actually and reasonably incurred. Such determination shall be made: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. by a
majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. by a committee of such
directors designated by a majority vote of such directors, even though less than a quorum; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. if there are no such directors, or if such directors so
direct, by independent legal counsel in a written opinion; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. by the holders of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation provides that we may purchase and maintain insurance policies on behalf of our directors
and officers against specified liabilities for actions taken in its capacities as such, including liabilities under the Securities Act. We have obtained directors&#146; and officers&#146; liability insurance to cover liabilities our directors and
officers may incur in connection with their services to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the
Securities Act of 1933 and is, therefore, unenforceable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exhibit Index that follows the signature page of this registration
statement lists the exhibits that are filed with this registration statement, and such Exhibit Index is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Undertakings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; notwithstanding the foregoing, any increase or decrease in the volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration
Fee&#148; table in the effective registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the
information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule 430A, shall be
deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or
made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 and (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act of 1933 and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Ramon, State of California, on July&nbsp;25, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GALENA BIOPHARMA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark W. Schwartz</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark W. Schwartz, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Mark W. Schwartz, Ph.D. as
his true and lawful attorney-in-fact and agent, with full power of substitution, for&nbsp;him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments)&nbsp;to this registration
statement on Form S-3, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, and all
post-effective amendments thereto, and to file the same and all prospectus supplements, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that
said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of
the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark W.
Schwartz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center">President, Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Mark W. Schwartz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;John T.
Burns&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Controller</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">John T. Burns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Sanford J.
Hillsberg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director, Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Sanford J. Hillsberg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;William L.
Ashton&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">William L. Ashton</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Richard
Chin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Richard Chin, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Irving M.
Einhorn&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Irving M. Einhorn</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Steven S.
Galliker&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Steven S. Galliker</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Rudolph
Nisi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Rudolph Nisi, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mary Ann
Gray&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">July&nbsp;25, 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Mary Ann Gray</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibits are filed with this registration statement or are incorporated by reference as part of this registration statement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of Registrant (formerly RXi Pharmaceuticals Corporation), as amended as of June 28, 2013 (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Form&nbsp;10-Q filed on
August&nbsp;9, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Ownership and Merger (incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Form&nbsp;8-K filed on September 21, 2011).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Galena Biopharma, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Form 10-Q filed on August 6, 2015).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated By-Laws of Galena Biopharma, Inc., as amended as of August 6, 2013 (incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Form 10-Q filed on August 9, 2013).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Fredrikson &amp; Byron, P.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Fredrikson &amp; Byron, P.A. (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Moss Adams LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on page II-4).</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d219508dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 25, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galena Biopharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2000 Crow Canyon Place, Suite 380 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Ramon, CA 94583 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being furnished to you
in connection with the Registration Statement on Form S-3 (the &#147;Registration Statement&#148;), including the prospectus that is part of the Registration Statement (the &#147;Prospectus&#148;), being filed by Galena Biopharma, Inc., a Delaware
corporation (the &#147;Company&#148;), with the Securities and Exchange Commission under the Securities Act of 1933, as amended, on or about the date hereof. We have been advised that the Registration Statement relates to the resale by the selling
stockholders named therein (the &#147;Selling Stockholders&#148;) of an aggregate of 3,658,012 issued and outstanding shares (the &#147;Shares&#148;) of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Common Stock&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with rendering this opinion, we have reviewed the following, as presented, and represented as being such, to us by the Company: (i) the
Company&#146;s certificate of incorporation, as amended to date; (ii) the Company&#146;s bylaws, as amended to date; (iii) the Warrants; and (iv) certain resolutions of the Company&#146;s Board of Directors pertaining to the issuance by the Company
of the Shares and the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined and relied upon the information set forth in the Registration Statement and such other records,
agreements, certificates, public officials, and documents as we have deemed necessary as a basis for the opinions expressed herein. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to
us as originals and the conformity with the original of all documents submitted to us as copies thereof. As to certain matters of fact relevant to the opinions expressed below, we have, without independent verification or further inquiry, relied
upon certificates and statements of officers of the Company. The opinions expressed herein are limited to matters governed by the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and upon the representations and information provided by the Company, we are of the opinion as of the date hereof that the Common
Shares have been duly authorized and are validly issued, fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this letter as an exhibit to
the Registration Statement and to the reference to this firm under the caption &#147;Legal Matters&#148; in the Prospectus. In giving this consent, we do not admit that we are within the category of persons whose consent is required by
Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations promulgated thereunder by the Commission. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fredrikson &amp; Byron, P.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher J. Melsha</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vice President</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>d219508dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> of our reports
dated March&nbsp;10, 2016, relating to the consolidated financial statements of Galena Biopharma, Inc. (the &#147;Company&#148;) and the effectiveness of the Company&#146;s internal control over financial reporting appearing in the Company&#146;s
Annual Report in Amendment No. 2 to the <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2015, filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Moss Adams LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portland, Oregon </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 25, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g219508bcpg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g219508bcpg01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 7 !U P$1  (1 0,1 ?_$ *4   $"!P$!
M       ("0$" P0&!PH%"P$!  (" P$!              (# 04$!@@'"1
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M"8?*/'W$T->4%)3J5N9 R5-+.7[##B<JL@UB;GE+:: +B0AS+JB"RO\ C0H
MFZ:[_P"VO'.)\OW62SWN=\5S$*M:TTU4QQ[:_)=%YUNG)-MLA)L[8VQ%M"\B
MM"?EXI@OF[B_W)LD6I VYC.Y8GD8OD>S(2[LP9?MG)\"UOF?C[NCD)9KC;&^
M/EGS0;+L.+:.2%$Z ?521JU,)>FO0? 3Q.UWJ4;C92V^U6U6ZGM !I4 D]^=
M5YIWVPW:>T>+C=8G[O+BUFLUJ.E$UQA^U^0_$Z[6,S/8EOVQ7#5LO;MPV[>=
MG2*MDW?:3X@H35FW8;Z0T5)0LD@)@.L(GV'$#)B!@KK[(+CAO*; ;'93V[2'
M'2VHUL[#\5YK?O/N%P+DS]ZCADFM'X34!)>T=1TR7F9RXSPEJFMW.G&Q!R]P
M)D>[8FV[GLLZIW<WQXOJX9!)$+8N+8 /?T%).W!OM#_:)!*()'$!#5MKOVX<
M/N3M=_)'_5TT:\_QO;3(?^@,QVKLTUCM/NI9BZV/R7I=YXY?Y >M!XIQN8YH
MO?;1Y>1668FU65ZW[>=OV!B=?'T@N*3FTN--AQ3,KY2-],0(G=EZ78HNNU$P
M% $4  >^OAC^%?\ W;;O;[20/V=\[Y!(W%WJDFK0>P= O246[67M'86AB>9K
MD0,$C*U:T4QPZ+LTXO<GL2<M<1VWF;#ERMIJVI]N4SMD*B9)2VYC84'MOW Q
M ?68R,>XJ0P"  >E0J Z\P<DXIN?$=Q?L]VPQR1DT<0:/%<"*]O49COS/H/B
MG*MFY;MC-WVV=KVN'G94$L/44[NG:E'I"(E&H[AKW#Y1'Q  K4  ?CK2-+C4
M/;0C\>\+M1+#YF?254U)81HB-$1HB-$1HB-$1HBU]?\ 8UI9+M*Z\>7]!1MS
MV7>T+)V[<MN2R*;AA-0\FU,U=LW*:I3%V'(H.T>X' ! 0$ '5T$DMG=1[C9.
M$=Q$,2,\?FN->,V^6,6%V2[UL:'+#[5\5QO^Z1PCN;A79&++C@9F2=6+;LA*
MXOM"^&TI(,KC;6=]2O,V';EPN6BI5C/K;0449(*C7U$42 &O7/L1S"RY'=R[
M-O[65(K5]*$#QZ+\_P#_ *:]M=^V;=H.5\?FD9:M)P83W88)M;$F1O<\N,H+
MX-OS**]H(E^G<S.7G+$<4,VXCYCN7U]$,R<M"% =Q40.;I3OKZ_R&W]N[2Z)
MVZW)FD^N2U:#(TC(MIU[5TCAM_R2XAU\@E M&@5]4T-.M:]R=0X@YI>0&7;6
MC.2T[QWY 7'/J'B;QBL/XW2MJWXR-:F(Y</[UN$/1@+O;0_I@J0I&A@25 !W
MZ^4<UX5OFY\>EWV"\FBVR$$MCN':9.RK6GJ5WWA_-_;2/G,.Q[-$';V]PUF,
M#TSW$C\4U[RSN_@9F;EYG^2RM&\F\*9.3R&]BG5[VS(0^2L>R$0T(W"VW*$
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M@T "O8,E'TXR:T%5F5*#M"H5 !J =.E/&@EZ_P ]5U4^Y ]Z4^ CT'H':E0
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M#/VK;Q86SD'BKB"5Y1\J+M6BFDU&RJ;-$CC'O'=)==!ZV:7/?[=HL?8'IJ%
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M9<@.R0MO&;1PCN=-+=*Y._=" &(0B  ;H;1$CSVF.47+BT<V9N]MSW)+\99
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MXZO[+_MA\K<=8PLV9OV_;IL2*8V]9]N(%>RTL]+=$"Y5;,DA':J9!N@H<?\
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MC*QD%%O964>M8F,CFZKR0D7KE%FS8,T0 RSMRX7,F@@W;)=35$*!HV225_I
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M>,DX.R)R<E[_ +KD+Y99.R';D]:%Y3[IJI<DQ&,;?*P=(2[1@@@R8$:.0V)
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;W^,M>^__ !GV_CN]*OX4U5CK5GGI]OMFO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g219508covpg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g219508covpg01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 7 !U P$1  (1 0,1 ?_$ *X   $#!0$! 0
M       "!@D! P<("@0%"P$!  (" P$!              (# 04$!@@'"1
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M\?6;E6S+OQKD2 C;ILB^H23MRYK;E44UV,S$2;<6KILL14IBE$2G$2&#J50
M, @(5U?;S2V5W'N5D[ISQ#$C/'GS7%O&;?,T;?=$NZV-#D%QK^J=PLNKA9:V
M)+ABIN1>6?%'D<66K?C22D&5R&MF.77E+"A;A<,U 7-*P,<H=FDJ(B*J:)
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M !(RGV]]-IW/K6[_ +;M_P#6Z5]NJL:^"S49<4F\<DV'CENTD+]NV LUI).
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M?-#& 'G$JL;<,/+.9)C&2K%^[AW)6,TW9ND5G$2]%,%BMGZ)#&,U7.B(#L,
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M1R5EQ"Z[4N^=>-W-R3L*6";,C_7D6:"+-BJ@X3,1(A"%W$ZCUU9<70N ,&@
M9!5VVVR6[B0XFI&96I^>.)G,W+.9[OY"0%TXOMJZL>W3 *<;K?E6CQ_+QUKV
MLN1:5CC7"W<)-H='*8'43?E,F;MD M=<^WO[:#;_ *,MJ"34T6MNMKNY]R^L
MU$.H !7ER6[_ "EQGD#/7$O(V-(**BXO(.0;+91_TQX]_NZ&G'!X]671^<V
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GF;O+\%/BU::T40J?H=?B_A_M;]_:-3\=_:_9JO\ 5XU_@K/51?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g219508txpg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g219508txpg03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!:P)U P$1  (1 0,1 ?_$ 0D   (!!0$! 0$
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M$HP<,Z[)3%<5;R->CW#=$YSNP52 @DV P".VOGM:Y%F^<S* TD/5F537/NL
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M /Z?#MMQ\^O'HVS7YA.GN)L(7KUY$O+9<L;2;%Q@X"8#E#B(E$@\1Y"7;8>
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M*<3,Q-]&"E36.\8D(83 8/#$0VX[ASOUIJ5SVN,R4<-OD?[EU2JN@:TL;3N
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M+EFTS*,R]E3VO]2<\.L-KF^5A)$(B[\2><],%G9O2Q*-HISZ2),M8"72;N)
M!A)M_"&G8:+?F6:IE4<3+4G=;G2W*"A@*;;GK"FXG4,PS2^5,P2VEPNM:'87
M$6_1-X-I%RBI^7>JH,KI#3S6C-JF>V6Z,0,3FXFB/YUMHLC>M%L^+Y6CLRA8
MIF)CYQ6#BYPE<,9R:8\"6<*)(-%2>%X2+E!)(%E$S&#N)F =^.VO=R/4YS[&
M93'&G:]S<5F$81&,=H)L!&V]?+:FX85NB:0R,PJ1*KGLQ!H&(DN-W)OYEZ;Q
M_@''ECQS1YV7<3B=@N4!;90[IM98Q,[=[7C./848BGJM#25A*Z\$"G*@?<FP
MB(AOK\NSG7N=T.?3J.0]AHY4UH#<!@088L4R,&PY0OZ+T=P<TYFW#ME972W#
M.YLASA-Q".+Z,)<(F/)>N=1/3=;)1Q!,VL[7E)&=J_TV49 >04?PE7.)D4I*
M6(BU$!,HY*"14TA.IW^&W;KZ=_$>CD4<RLF2GX)4P2XV0>^$2&VW@6Q, O@V
M?+_F$_-)&7,J&FJG2!,=O;*C#$X;(G9>FFO3=>526XQW<.V<TP9$7;,XO#!)
MI1C%.365:ND&YFB9#LU@,0BAB&$>P-AUI4<1\MI?5G&672ZN$#$>+$PNOOW!
M31\!<UJQ6LDS83:(.C9Y3&VWW1ALO6T0?33)IV:F0]GL,:UB[:V=N?G&)1>.
M2-#H17SPFU*Y,U!BX.JB %,9,YB$$![> ^5,XBM=25)I)!,Z3- @2 71,+KQ
M"^T6KUZ'@2RCF4TO-ZB&7U,G&'0)PF$0+!;W+EJM H]2>Q^1K1:W,M)UG'X,
M$ :UA4C9W..Y2358L%4W3E%4&S))-,3*B<FYA[NNC/M29OAHZ>B#&550"076
M@!H!-D1$VV".\JND.'^1>OUL[,W/FY=1&QC/*=:<.^ LMLW+88?"Z]\F9XV/
MW;IM#1J:9X]"X,W:$NX.K&'D19N!;-S-4P2(F8I%53%(I\40Y[:B=K*7E4J2
MW,V-?5.L>9;@6QC"-L#;M N6M/PRFZAK:S-,@>Z502Y;H->TM,81ANYHWJU3
M EI)#LY)I*5Y^]<-*S('@FRSOYT:,;:Z!G%*.556Z;415>CW%"E,)R!L8 VX
MZYI7$*@G5$R7,EO;*;C&(W19>-]UH6F8\$ZNDRBEFRYH.853Y9AM_67'=?>L
MA&8$L<I-O8.(GZ[*&AFSQ6<>-1D56T2\;/21IHMZF+?VL[DSLW= Y"&3$H";
M?8-5F:YHZ.0*N=)> ]P#02(NB(APML$+;;>ZMJ'@IF\_-GY733FF=+DESW&(
M <+"+=L=RPUHQ3,TN +.S\O"H**S<G H0J:BRTJY=PSD6KY5N9,@LDVR.X&*
M<QQW >7>W#7H95K"ASVJ-+)DO#0T$ON;:+!OB>9>+J/AI7:3RH9KF%0TS^V#
M,%Y.^ZR 7/D]MP[0VY\./G[-]]?2&6;FBSG7Q3^R+CXH32//EY.'EY]NLW2Y
MFZSG6[&MNPIP@!N'#C_B:Q,MYN!72T,'T2FT^?R=^0!MZ]9.EOC"!BNJ6]D+
M6IPA@WXAMZM90<-AZ5NV>R,'-3:6P[\.T./V]9D&/D]]=\I\H@>+!/%Y^H?)
MYM9ESHD8>^M8@/+@SOI@@\>>_#69Q$^1WUL+#'#WTWORW#?EK)S28^*NQF%P
M#L(BGR!\D=O7P\NLH&%RZ6 7P4^X!^)#[8_@U4M(V+I:\#Z-B>*/Q0^S[_GU
MB0=W?72UX,/%L37V=FLGM,?*(76T8AB#;.=/%^2'X//Z=8=G^>5TAO)9SJ='
MB/EXC\&LG,MAB*Z98A:&I\ X!P[/+K%S8& >>^MQRM3"0AY.W[VJ0WN75+<0
MWR4R7T!R+\'HU&&'TBM@8BQJ;+MW_)\GMUB1;Y170T$B(%B=+RY^7R>7698+
M\1BM0UQ'DIE/?8NWE\WEUB]NS&5URPX,M;;SIPF^X\?)]_6$!YY6S<6QJ:1#
MB//EO]G9K-T 88S%=LK&!#"F2]OV>75"T><5T",+DTGR+MQX\>>W/T#K)S 3
M#$5T2W. PAL4XGS'T=OI\^VCY;0(8K5TMF.%A;WTXCN/+R]OHUS^,RP6\JZ&
MF:ZRYJ9* @/9R\GG#5"^:=BW!F'Z2;2WY[;<1^#5'.F70M6[738>4F0[VX>K
MR?XNLL4T;%T-[6'E)LHCW0WX</PZR>^8#:MF=LWZ5B9 1W ./,/LY:R+YFP!
M;M=.)L=WDX7Y(<OL$?1K/%,6[3/NQ)@.0<N0:S=VAN"ZY<R:V +K>9.%[VW(
M-9$3(VKH#YSC$0*:)WOB\ Y?>UD>TBMF&H\T=Y,DY<=M]]9GMMERV9VAMF"!
M32>_>#]Y#X#:R)FDQ6[1$IL@<./E^]JI,X<RW!A<F4>W;[.6L7.FWKH8;4Z
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M%;3]6DV"%;DHN+04;NB)!)-%R]XC@-]M$6<QS[I;INI?SK7;<ZL>:,43V*L
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MD2C<T0'(K@Z>(']<D\'H?]OK)J#43S>]Y_S%(,\T="F+T[P "&]BL'(>!)
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M373O4">L*V>G.92HH3E9@+=;)NHP]LF#C91C@@!>P"ZRID%UG":(E 4O&W2
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MMSS)P+)QCS*<GOZN@ "*%]KS9^.E*3^UHF')0H_[N;[CK(\-M7$@B1+L_/\
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M3.)DC?*( ;#KYO.-)9UD$L3,PEEC28 BUH.R)V1V+TZ2NHLP?_XTR)Z"O>?
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M_P!9S+3UX.L,F,P_:MS51Q#M:@]93_S7&P",^HBB6<<OVI%53;F<=Y$J:I5
M P@)%]'P'< '[VWW!XZ(JZ(C1$:(C1$:(C1$:(O-O49T_LNH)#%\1-.(@U8I
MN2V%OMM>G(H99A=*RG!3D)*U91$5D4T/G%*9 ?%.!P)X>X!OL($7SN@?==Y'
MI$1-(06::?D23:7W*_U?$S72)&TP]?P]DBGL:?"U:;;L9AJO-W?'$>V\*-F!
M$@KM2)(K$V*(B19)#W7ML9N8ZL)9;K3VCM[8I>7%ZE:F^=]0;:5DL7J8XEZ[
M 7T)0K6'I<> $<Q30B0BT3$R!N\&QM$73>F;W=KW#L8HVN68K\J_8R.-U8YY
MBZ_WVH$L##&E?6K\82^E=2;HTZG+HJ^([9%[K,3[\#;[@1>3^GGW:.8Y/&=3
MD,GO\:XYLV/YN]2V/Z5"4ATS3L3I?J*L6580.HT[2;<-<AP,@V!N!V+4R21T
MG'?./B )=$79WGNV<J.YZE7EKE;']>R WR)8[_9YJO52P-(:HH6&QUB75I.*
M:VK+JQWT&1:UOO%CY@%R!(N570" B!=$62@?=GV&'DX9-:^X_EJTO;L>6NZ>
MUT1V6R2Z5 SC>\G#7(Z33D@(C"V&N7E9@Y!<%1*[1(L3XGQ (L3+>ZWLSJHH
MMT\U*2=ZK.7I&S4>0=-9JO5U/"$?4K%1<7X(M*=<D$Y67@<60-F<J,5RJ$.L
M[[AU ';<"+U/9^D>8==/&$<4URS0+VW8+EZC9X)>_L)JT8\LDS70<%=1=M@?
MG%&6EJ\H1^J#0IW!EVIDT3[B8F^B+5>D3H9<].&0[5DNV6ZNY LMJHT% ).F
MU2",5J$H6_90OMECJ>X=.7R\11C+Y%(QCF)!*JFU8E%8YS&^*1<F?>[%;.ZB
MW@R76M1\Z%PZD+E,V..IYVKVUN<SY,6R+68.TKI/2OIRMP*A&[.39K*F2?HI
MF[@) (!HBP[_ -W-E:17L%W=W_"S^_W6;R06=H4EC67==/5:JV0J)4:*=:BT
M,TS[>UN<.E2&SQ)^Y6.0ZKYZGW0(H Z(LOASW:L]BG.-!R:XRTI98"JOJ;9W
M$>Z7M+22;V2JXD;8L4B:^Q2E#5YO37[9J#GP%TU%4^^8G'8I@(NN3G0HE/93
MRGE$]H@6LYD+J'QUF./FVM9[EMK-<I.(V&,GE3C[&+CVQ)W(K(+.TUTA323*
ML)#)F'<1(O&Z7NY;OT^T=M9V$U,9LG\;SN/%Z/6X]C/VP+C'TYY;TT%LJ4BQ
M6:/C;:0B%O,J+9BX:^"Z13<$,84@+HBU& ]V-GO)^,\:*6F_U3%J@3\)?)6E
M?1>2C9"GR$=GX^9S1S%C7I@(TY96.*1B=FZ56+'*&/W%%-Q#1%Z&-[MG(1$\
MIO87+E'I5OD:@A$X+MM3Q\X:/L;6R!S5;LNUB\2S=:3]EE)7V>UJ14@#8&_M
M#91;NB7Q-@(LFK[LUY#Y H=CIF219U:#AL9IS\%(R-O3.TL6-A7?!*5!",E$
M8]-K;)U47,D1Z"IS]\X=X>&Q$]:_=OREDL]2DW5SH<U#$Q-2,>9$);:*I*SE
MHDZ3G1WFM.9:O@?)(BTG7<BHQ>-WA%_$222'<0 Q1(N*67W?&8GO4UD5*L_5
M<EBK)E R0\E<@6JC*R;BHCDS/X74*;C)FUF&PP-ZK5=8@L6142%F<ZB!B$*9
M+;1%N%H]U78)6?K$DRS.Y>1[%J^KD[&R[FV,435PN4([(\7,Q"<'+H)_343L
M0;/%G(F0<"/?  XE$B^Q$F3PXAZGN<_<8+D[ZAN^<X%;F#OG-S,<VVXCVCJ\
MDD5#(><%G._9.YE_.L]Z$&_O#NKH-]O[*HC_ /EFO<-?VOPRE%^DJ4M< </Y
M2OYNUPR7[6>20/'7@\?1]WA]W7Z 9<N6<,PXG;XKY5V%A@P%PA?%'+R_!J,-
M.;P>E5Q_F%'V] VG&P]*C$-K"CU?!H!(V ]*8_S#TE4WVY;^K_$U,)&X]*HZ
M= PP'I1WA\_W=,,C<>E5[?\ ,/2C?S#]K3#3C8>E3VY/[L]*-]O*'JTA3[CT
MIV_YAZ4=X?/]W3#3[CTIV_YAZ4=X?/\ =TPR-QZ4[?\ ,/2J\P 1X<1$#".Q
M0VV*;Q"[_&+L;EMRWU3_ ,:4XS7.PQ$!&VU2)Q=9@,%]-^G;I\P!DSI.R)>K
MO1;M7KI$E?5VKYIDK>K'P-FS1-S<=&XZP_BRAD*5&W&DF;A12:=* H=A\40$
MO+7Y9JC5.;4F:RZ:AGL>U@Q.EM;;@'E/<[8!<!M7Z#D61TE=0XIS"'D>5';L
M _*LUU[=#N,,(I9 R!@;(<?-4S%%YQGA#*6-ED9MU/T3*5AHZ$O*.OI5*KJ-
M;"C)3#=R9=N@5/YO, )["  .M]$ZTJ\ZK)-!FLLB?4,=,ENL'B8H 0'FB C>
M;U&>:3=2RW3,N([-L 0;3&%\3^)?.#'&1[UB*\UO)F.+-(4V\U"2)+0<_$*"
MBX;.$#AXJ*@"(INHQT01*LW5W353,)3 (<OO<RH).<=KDU:&&0YI$2(KXS+,
MRK\OK0#'$#L7[U_=N]:TMUK]/D+D&VT*4HMRBW:U9GUCM#(5&Y2\<D07=AHJ
MZY_:GL2MOWE@ O=:.!,F!S;;:_CW5NGAIO.IE R<V:R,1"\#<>7\87[KE->_
M,*03WM+77?X+Z'A\K???AY.8!ML8!_%=[7RKXQ7H=:F#EJH6C;E(74%;,N4N
MI-RW52?*#U_ .L%*9)S]7WPT17:&Y;J?5%*.T/3IL5V;5.7Y0>OX-9FY:I@>
M>LU=ODJ\O(-5-ZUEWE7E^4'K^#53<M5.&J%6:JZA61HB-$1HB-$7SC'W5'1,
MO/=.]H<XP=/[%TN6_*UPQ)-/K'+N9&.<9I^>QR)7YYVHMXMGITTI8')PBW@J
MM4%#]Y,H#ON1:S">Z+Z/ZUBN5Q#!L\I1=><9$HF3JI/1^3)IA>,56?&,B]E,
M?!BNW,2-Y>H154<R;@&K8AE"%(L8IN\&VQ%F+%[IOHIN& <>]-5KH%CL6+\8
MYP;=0U82F+O87EC^M!&R.+:]EI6T+/!EY:-GYMXHI(,EE!;/"F[BA!*  !%9
M:?=1=)EHSG9^HA9/+,)DRSS]PM0R57RQ:8%E7+7D&E)8]N=CJ31HX!6NR4_5
M$"-U/ 4\%(2@=%-,^XZ(N]=*G1;@'HMB;G6>G2MS5'I]YF(RQ2E)4M,Y,U-A
M96$0E$REDK\-,/'B,)-W$R)7DXL@)1DY#=RJ J&$1(O6?9QX^?[^B+0%,9X^
M5R6CF$]/@C93;TESC9"^F8(_29*ANYIO97-41D_R8L*M.M$W9DN0K$ VB+SE
MDKH.Z=,L+]5B]R@;(Y/UHT"CXUSR+&W3<82=JN/(J6A:PVA2M7*?T:=MXZ;<
M$57:=Q1;O@)A$0#1%S WNL>D N0,G9 0JEK9.\O5*0JMWK3.WR"%-D'$S2F6
M/)BYLH0"",9?9.HQJ#1>305(JH"13;=[<1(MRN'N\>G&Y2^%YY1#(M8E,'TB
MK8OA'=%R7:J>M=<84M2.<UW'F5%85ZV7R!46#Z+1<^R/3"!ERF,(B!C )%Y8
MS?[FS -KQ#U+X^PH\D\9S'4BLHI(FG)*1LE(H0361(S(=U#']8249.:FI:IM
MHHX5%NXV(Y5\0NP!W=$7:8WW5_2W'PE*9'5R\^M=,S>[ZAC93>Y9M+O*EKR9
M(T!;%LFYNMW67&4LT ]QTO\ ,IHYQ^9@CTR)E*7N[Z(EXCW2W1; 4F1Q[%TV
MX(5B8J73M1WC3ZPK,=4]>Z6;L^R!B!J1VH\%9-:)LDBJH[4 >^_2'PUA,4-M
M$7TN -@ /('W.SGQT15T1&B(T1&B(T1&B(T1&B+RCU29=RIC0<.UK#L+0I.Z
M9?R<TQ^W?Y(6G0K-<9JPTG+.9QRRKJS64E5$!8%3*V361$XJ=[O@!1T1?.^E
M>]9R)<YO'S)K@@QV\A U!U9V,>55R[NTM9'URBI$<02+VP1OMK2"D:<=-1!5
MB^7,=P0ACD,41T1/)^\UR-'R=EA[&PP21RYPE Y0J85]_:Y60IMLM69B8OBL
M892AEI1MX5B:LS&7<&*ZC4A=IG()DTP*8Q%QF$]X3G3)EWAI.7E:-5:FKAVY
M1TE0H:4L-;D)W*U+ZE*C0?I#69-"5DY!LV;UR8*J^C07=J%8BH)C]TQ3 1>@
MK;[S3(T+"W88_#L<K8L4W>D81RXB4TG)QN/<S9!NKMC$"Y6!_#-96E1./&J,
MS(&*\0615D6R)E2;B(D6YY?ZH<O6KHEQ/G.EU]Y4\EV3.F*:V:H1=F9UUA:4
ME,N$JC^$1LZYIYI$UNZQ[<3&5.9SX**PD,8XE$PD7A'J3ZCNIF2S)G.F9$FK
M-@2,C<D=$<+'8^JG5?7\:1T; W>"S ]LKEIG0:RSCJ:%S?PC<'351N8[H6*9
M2G#Q T1;9<I?,$VOT]4/$UFZ@,JLAQ7U$7NV4?%?7]'S%PF)BKS].:1WB9^8
MP+AI>9".:R1T64*!&HM570=XWQ1W(GHWJ(?2^.ND>NH=;+^4ZF[9$J2=;JK[
M)U:H5;K5;99'=,Y^Q=2:4N=F^R%,T6%(E5G,<8A%YB?:K&;I *AU4R+T%[PK
M-N:,99BB(K&=VGV !TBY-NK:HQ4ZC78RPW:(S9@V#B))5\Z:O6T:[^;)UXR(
MY."A44'JGQ3;Z(N694ZDNJL<M9KK&1&\OTV5,M'Z/XV8=U?)L5DQ#'%-R1E.
M]5_(^38N4BH")1ILQ(L&B48I)JIJ%CDTR/>\4$P$"+Z/=)BM%9MLFU;&74I<
M>I"MU^P1H-I:ZVDN25:5)/X5!9U66N442B-N:JJE*[,B9==1@984A,&X% B\
M>,<Q=8&*,,^\"F:TJZZL<SXDS#:PI<9)+Q5)80,,KB*L6Z+@JQ7VD=))2,97
M91^"#>/+^;)$RACG4\0P[D6?SCU RY:Z:S9XRI/='=6QO@BM6?-BU5L\3(KD
ML^6K?$Q=6J5>LZ[)DQ1N3U&LO&+4Y4TUVIYHAR" E!0"+6:!GGK%IN(NFI7'
M5'BNIV+R7GFUPDQ8WF:*S.3](Q$_^F4O1ZE>;E&Q<]'RMTK\0R9(RTOXHD3=
M)^SJ=Y10#:(OL4U.LHV;J.4 ;.5$4CN&P*@N#=<Q"F50!<"D!<$5!$H'   V
MVX &B)C1$:(C1$;!Y-$1HBQDP(!&2._\PN>([[!^,F#CMOOS\FK2W8)S''R0
MY5F0,L@[E^$'WB/1GU3Y$ZY>IN\T;"%SM-/M&1ADZ]8HDT.K&2T>:OPC<'3%
M0\D0YD 5;G+\8 $#%'AK^L= ZGTWEVFJ>1F$\,FM:8Q)WDK\#UCD%;7YFY\@
M'#B7C4.@+K1V#_Y<\A?:A0_]::^V]]]&FV55LP\L>I?.G3.?4_ZN3)+F0OLZ
MU<'0%UI=G3AD0WH"&_JKI[[:1^]L[_4GL'4>VG/0.M'[0+K3_O;\B?:AOZJZ
M>^VD?O;/P[B>P=1_=_Q*O[0+K3_O;LB?:AOZJZCWVTA][9^'<3V#J/[O^)'[
M0+K4#_Z;\A^L(;^JFI]]M(?>V?AW$&F]0S+72".A'[0/K4_O;\A_:AO/_P"5
M-1[[:0^]L[_4@TQJ#;(/>5AN@'K3_O;L@CZ4X<?+Y)34C6VD?OC!^',H]U]0
M_8'O*H= 76H ?_QPR"''EX,.._\ _M-/?;2'WR6I&E]0_8'O*O[0+K4_O<L@
M_P 9A_ZJ:>^VD/OC$]U]0?8GO(_:!=:?][ED'^,P_P#533WVTA]\8GNOJ#[$
M]Y4-T ]:9RF*/3=D$X 4VQNY$ /Q@[A@*F$H G,(&Y\-@U+M<:1,G ZLE%H.
M("V,1RK0:>S^4R D$GN+V[$NO>R0N)L;X/8].,2- Q')Q<UCY)SAW'[N>K\Q
M%3;2PMYLE@6E!=&EGDFS3%XL8!5>)=XAQ HB&OA*B5PUS"NF9I/J9K*FH_:0
MFN#39".$; +AL-J^DI/>Z12"F9(;@9=XK8BV-_/WK%J&?:I[U/J5@4JSDS!$
MN2(6N#W(5A2IE$IE,)=;XZ;@S&XW<T3)%-8)Y!H4$4%E]Q32W NPCKT,HJN&
MN1SB[+:P%X :'.<YV%H^BR/DMVD#;:O,KY6O<P/9EA$N,38!$[SO69Z-?=1Y
M8R1D5I)=2M*L..<90+IFNK5'3ABE;\J2G>!1*JQ:3%T[4B8$.[O)2!^X":(]
MQ,!.;AS:SXFY1EU":;(GB=6S 1C'T>7E.X+KR'1]:VH]8S9NVT;U^RG#N)(C
M&M=AV32)BX9*,B6\1#0$*@5C U:$9$*5I#0K)/8B#5 /E&'=1901.<1,(CK^
M;IU1.JISY\]SG3'F)),3$[S^$%^H]C)D,#)0 ;"X+M91X@ [=[;<=N6PCN'W
M-<S[^XL^M3!RU4+07*0O;J"MF7*74FY;*X/E%]'WAU@I"8)S]7WPT4J4@ .^
MX;\OOZARW4FJJ4=H>G38KLVJ<OR@]?P:S-RU3 \]9J[?)50'B'K^#0W+67M4
MX?B?W[61VK52AJI5FJNH5D:(C1$:(C1$:(C;\.B(V[.S1$;!Y-$1L'DT1&B(
MV#GMQ\NB(T1&B(VT14V#R!HBKHB-@\FB(T1&B(T1&B(T1&B(T1&B(T1*N&+)
MVHU5=LVKI5DM[2R4<-TEE&CCNB3QVIU"&,W6[AA#OD$#;#MOHBUDU"HHN8A\
M-+J@/ZZ"Y*^]"NQ!7L"1TLHLX^970- <10+KKG.?V<R?>.<PCQ$1T1<(QIT?
MX4QA8[Q:V<7*W2=O\>$-,NLC2"%P*VK19E>P!6(YN^8IH)P0S:_M(I+%64,J
M0@B<>Z&B+NK;'>/VQ6(-J+3FP1@NC1H(5B%1"/,^,F9Z9B";$OL@O#(D%7N=
MT5!*7O;[!HBR3FI55XSF(]Y6:^[86%R9Y8&+F&CEV<X[,1%,SJ8;*MC(R;DR
M;=,HG7*<PE(4-]@#8BF2K5=0BV,(A 0J,+&';JQL0E%,4XN/4:*^.T48L"(
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M3ZPMF28VN8#!NXNY.6X;=Z]G+<\H\T=AD,<UVXD6\W4OJ4([II" FV^-MN
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ME\:R]Y%&^[^/T^Y\5,\Q<YN0Y52QE-GJA99.X1%?3ETI4' ,U<2ILY(R;FQ
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M;QK8'8%;[$.L(D-\31%YA6]U?5EY #I9GM;"#/C.7QO(QL35H:,D+"RF8!O
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MT1&B(T1&B(T1&B(T1&B*FP#MN <.(<.7HT15T1 AOP'B \! >W1%0
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M/^Y>WS_%U7Q2WQV&*G]:^UTP!2EQ'C@-A^88G?G_ "+V_P #K/LV&YA6C0\
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M-^*@?P)OP:I'D5E,0"[@/?)Z^\'PZ1Y%MWU,7N\=CE#T<?AU!BICR*\-O\>
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MVRTI-IX\SY.E?NYE\!:SD%X1LS*5VNH!$H*Q%;IMVZ""IA K5SW"E*<0(IS
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M80$N1(.)^)WB7':5TS,HT_,<'&:XD#SE*/1511YTG(Q?D[ 7(+  ^+R$.Y&
M #JL[B5J!]0)TRED$0AY%_*K-RK((0[1]V]'[2FC<?TE9(XB!A'Z?L1$PA\G
M<PQ8F.  /(>&HD\3,^8^+*>2V6UWF;E4Y-D$Q\!/>(_G*\.BJD\ ^A>23  B
M8A?K 8BF41V 1*F,5W"[[=@=FLW<3]31<_L9/:O?!OB["M7Y)D+1@]8F>DI
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MADX@NE3B0(#QA=T*X.B+!H!L$;-!_ONXX\AX\/-JOQ6U3?&5'ZIZUI_;-PW
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M#5!_EJT;;\0^?9+CRY#[5K)^0O!B'6<ZU;K,$7N"PL_AJA6ELFTE'-K59)J
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M$<'0 O(2AMOKE&99:))J.WDF4UT"[$,/2NZHTWG<FJ;2S:6H$QPQ-:&&+AO
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MBW!*G3^_][5' 0CM6K22ZU,%^4'IUFNAOE!.%$=@X_9OK-Y(,-D%U  7)@
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M2G9'3=>ML#)=^*E)02@5PH<Q@W,(]HZYW\.*U[JAYF,$J8)F%WTR9FQ^]@V
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MK3.U&@4K#--0N=FDI"L5*5O%@>.F;N9@FC&)BJY"KK*KG7V 0 H (CH&$B]
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MJZ(C2(1&G,B-+41J#$(J:$D) +&RQC)LE#D$2F[Z&QBCL(?CZ8;;AY0X:TD
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MW>@6:]-8GI:BJY<AJTFK*5A'I^L%LEYCYEE'[E65COI.VL*22/LYTO#%$P*
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MUB5,&J%6!5=0K(T1&B(T1&B*FP?9O]T>W1$=T.6P?9^'1%78-$5-OLW'1$;
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M3<:?85<<Q5$DU)P#RT1R:CEVDQ=P+&(7GG;]"849DAU"(0K91UW/:/%% O?
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M%>28.LPMRA4*U?:[]%+O1;GCV=5:0EPIU@A.Z06JBR H+)$53,!BZ(O!F/\
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M\>3_ (?3MI'VHZ4]2J.5'MC+^;&O\>3_ (?3MI'VPZ4]2J.54]L8@._MC?\
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M 1#;@//T_@UD:?;9'G72R9,(M9#NIL@CW@W /1PUDXD MP@KJ8\B!P6IU(1
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ME]J(1(3I0X!R[!'<1'CY>?EU1P<RR]=+7S8603 <@WVY=FL2XQY5LQT[D3A
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MY:%;0'<8A7^"#\'GUG[:RWSN^I;I?-P;9-G.FTZ-:A PFB%@ @;[=XNYO,
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M:R?4,*N*.:#;<F2,'8?*3#?8!#\<+V\^S5.V8M6TDWZ)L4Y&3C?Y >?XV_P
M&LW/8;ELVFF;2F2LU^U,.&VW';T[[[:S+V<A6[)! Y5,#1?@/A_=_!JAF-.Y
M;B2_:F@;*B4-RE#T"._VO-JO:,6C9;XP*G(@J \2A]WAJCI@A8NF7+=M,4R"
M:@[!L'#GS]6V^LL0"V#'13!"F#?O;!Y #6;B-BU:T_2,5+JJT1HBMV]?V>G5
M6EL/%N40)\JU8,;' 'FSUDL]##8DVP/CU\)1@,X1D(?%=FB07%\#4X<E!3[O
MGU(#2;[4(B("":"3CSN7C$LDP%Y'HI.9!J#IM[6P;+E,=!9VW!056R2J9#&*
M=0I2F !V'AH6F/E*0 -T4N[L,%'QGSW(3D,QAMBF&6=R3)M%]U0=DC?.*ZZ;
M78X\ 'O<1TPN\X]"G"%;"6*OV=J=]6YZ%L#)-44#/(.382S4BY0 3(J.&*[A
M$JI2B B7??;5<+_.*KA;N"G6F(EN60.O+QK<L.5-26%9ZT3+&I+)@JD:2%14
M@, 62^,451* EXAN&F%_G%3!NX*4\@Q3*T.L_:$+(G33C5#ND"$>J+)BJBDS
M$5=G:BB11.4"=X3%#<.&K-BV\DJ!^? A2*.VB"S5LX=-TG+XZI62"BR:3EX9
M!,5EB-D#F(JX,BB G.! 'NEXCL :.<V&T*T&.M  5C&1CY(BRD:^92";9TNQ
M<'8NF[M-!ZV-W'3-<[<ZA4738VP'3-L8IN @&HPO\Y5PM&Q9#;[-M1!_G=Y3
M!NY&WH^T&D'^=WE$&[D;>C[0:0?YW>2#=RQ!9N&,Y39EEXH[M9RX9)-"/V9G
M"CMHGXSIJFCXWBJ.6R(@=1,"B8A>(@ :F#_.[RC"R^ 31'K15XNQ3>-%'C5)
M%5RS371.[;$<][V=1PW*<5D4UP3-W!,4 /L.W+40=YW>4^)R*KITV9-UW;M=
M!HU;(JN'3ERJD@V;MTB"=1=PY5,5%NDF4O>,8P[ 4!'6D#"^*@!D8@!8!>\4
MUM#M;(XMU60KCWN^Q3ZU@B$H5X81.'<:2AW96+@1[@_)./R?3I!6@U91I-P\
M@5JI'2T4_(_:F?1YF3]J[*_9)*%36>LS-UE/:FR9S@43D[Q"F$ $>.JX2?\
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M;.N2#<BZ)0.8D.HX6-L0HB%8J(",=J^2_3-C+WI?0#2LN8"AL4Y(@;+U,2^
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MV2S\ !_RO7X-MP_7$^X^C7][Z<?*FZ7IV6Q$AOXE_+F<T\_VY.BT>4=JX;L
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M208.@OP)]9N=,V0/5AU 1$%E[),/#Q^2IQ"/BXVW3#5@Q0%0AO :-DW($02
MYA$"AP#?7]B:(R#(9^FI-154['N+;R OYZU;F^;4>:ND4\UP$;@5Y<?=1?4
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M\O3Z'3*BO( W5:)OG=9KC"&>.FS=?\>2;+.FAS)@;B)!#7\Z9Q6RZW,'SI8
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/B(T1&B(T1&B(T1&B+__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
